AP271A - New pyridones and the use of pyridones in chemotherapy. - Google Patents

New pyridones and the use of pyridones in chemotherapy. Download PDF

Info

Publication number
AP271A
AP271A APAP/P/1991/000243A AP9100243A AP271A AP 271 A AP271 A AP 271A AP 9100243 A AP9100243 A AP 9100243A AP 271 A AP271 A AP 271A
Authority
AP
ARIPO
Prior art keywords
alkyl
group
phenyl
hydrogen
optionally substituted
Prior art date
Application number
APAP/P/1991/000243A
Other versions
AP9100243A0 (en
Inventor
John Fredrick Batchelor
Clive Leonard Yeates
Original Assignee
The Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Wellcome Foundation Ltd filed Critical The Wellcome Foundation Ltd
Publication of AP9100243A0 publication Critical patent/AP9100243A0/en
Application granted granted Critical
Publication of AP271A publication Critical patent/AP271A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/68—One oxygen atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C07D213/85—Nitriles in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C07D309/38—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms one oxygen atom in position 2 or 4, e.g. pyrones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C07D309/40—Oxygen atoms attached in positions 3 and 4, e.g. maltol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A compound

Description

The present invention relates to heterocyclic compounds and their use in chemotherapy. More specifically this invention is concerned with certain 4-pyridone derivatives, processes for their preparation, pharmaceutical formulations thereof and their use in the chemotherapy of certain parasitic infections.
A group of 3,5-dihalo-2,6-dia1ky1-4-pyridinol derivatives (the tautomeric form of 4-pyridones) is described in US Patent No. 3,206,358 as having anticoccidial activity.
European Patent aforementioned naphthoquinones ratio.
Application No. 123239 discloses 4-pyridinol derivatives wi e.g. antimalarial naphthoquinones combinations of the th antiprotozoal , in a potentiating
Parasitic protozoal infections are responsible for a wide variety of diseases of medical and veterinary importance, including malaria in man and various coccidioses in birds, fish and mammals. Many of the diseases are life-threatening to the host and cause considerable economic loss in animal husbandry. Parasitic protozoa include the Apicomplexa, such as species of Eimeria, Theileria, Babesia, Cryptosporidium, Toxoplasma, and Plasmodium; and the Mastigophora such as species of Leishmania. Another parasitic organism of increasing concern is Pneumocystis carinii. which can cause an often-fatal pneumonia in immunodeficient or immunocompromised hosts, including those infected with HIV. The classification of this organism is unclear and there is still uncertainty as to whether it is a protozoan or a fungus.
We have now found a novel class of 4-pyridone derivatives which exhibit activity against protozoa, in particular against the malarial parasite Plasmodium falciparum, and species of Eimeria as well as against the parasitic organism Pneumocystis carinii.
JB/LRB/26th February 1991
PA1137
Thus, in a first aspect the present invention provides a compound of formula (1):-
wherein
R1 represents a hydrogen or halogen atom, or a cyano group;
R represents a carbocyclic group having 6 to 10 ring atoms and containing at least one aromatic ring; or a heterocyclic group having 5 to 10 ring atoms, including 1 to 4 heteroatoms selected from 0,N and S, and containing at least one aromatic ring, said carbocyclic and heterocyclic groups being optionally substituted by a substituent selected from halogen, cyano, nitro, amino, mono-or di-C^alkylamino, C|_4alkyl, haloC^alkyl, C|_4alkoxy, Cj_4alkylsulphonyl, C _^a 1 ky 1 th io, C^alkanoyl, pyridyl optionally substituted by haloC^alkyl, pyridyloxy optionally substituted by ha loC^^alky1 or the carbocyclic or heterocyclic group R^ is optionally substituted by a group
JB/LRB/26th February 1991
AP Ο 00 2 7 1
- 3 - P41137 wherein fl
X represents -0-, -C-, S(O)m, -CH20-, -OCHg-, -CH2S(0)m,
-S(O)mCH2-, -CYZ(CH2)p or -(CH2)pCYZ, or X is a single bond linking the phenyl groups;
Y and Z independently represent hydrogen, halogen or C^alkyl;
r6 represents halogen, cyano, nitro, amino, mono- or di-(C, .) alkylamino, Cj_4alkyl, halo(Cj_4)alkyl, C|_4alkoxy or halo(C1_4)alkoxy, or S(0)mC1-4 alkyl;
n is zero or an integer from 1 to 5;
m is zero, one or two; and p is zero or one;
the carbocyclic or heterocyclic group R being optionally further substituted by one or two substituents selected from halogen, cyano, nitro, amino, mono- or di-(Cj_4)a1kylamino, 4alkyl, halo(Cj_4)a1kyl, C|_4alkoxy and C^aIky1thio;
or R represents a C^gCycloalkyl group or a C^cycloalkyl- Chalky! group', wherein the cycloalkyl group or moiety is optionally substituted byCi-galkyl, C-^cycloalkyl or by a phenyl group which may itself be optionally substituted by (R^)n as defined above;
or R represents a C|_|Qalkyl group, optionally substituted by hydroxy or C^galkoxy, or by a carbocyclic or heterocyclic group as defined above;
4
R and R , which may be the same or different, each represent
JB/LRB/26th February 1991
ΡΑ1137
ΜΑ a hydrogen or halogen atom, or a Cy_^a1kyl group optionally substituted by 1 to 3 halogen atoms; and r5 represents a hydrogen atom, a hydroxyl group, or a ^alkyl group, optionally substituted by hydroxy, carboxy, amino or mono- or di(C^^)alkyl amino, and salts and other physiologically functional derivatives thereof.
In the above definitions, halogen includes fluorine, chlorine, bromine and iodine. Alkyl groups and moieties include straight and branched chains. A carbocyclic group may be for example phenyl, naphthyl or tetrahydronaphthyl. A heterocyclic group may be for example furyl, thienyl or pyridyl. Preferred substituents on an aromatic carbocyclic or heterocyclic group R include phenyl, pyridyl, halogen, cyano, nitro, amino, mono- or di-(C)aIky1-amino, ^alkyl, halo-(C^4)alkyl, C^alkoxy, phenoxy, C|_4 alkylsulphonyl, 4 alkylthio, C^alkanoyl, phenylsulphonyl, phenylthio and benzoyl, wherein a phenyl group or moiety or a pyridyl group in the aforementioned substituents may itself be further optionally substituted by halogen, cyano, nitro, amino, mono- or di-(Cj_^)a1kylamino, C^alkyl, ha lo-) a 1 ky 1, Cj^alkoxy, halo(C|_^)alkoxy, or -S(0)mC_^aIky1, where m is zero, 1 or 2.
A halo alkyl substituent present in the group preferably carries from one to three halogen atoms eg. fluorine, chlorine or bromine.
It will be appreciated that compounds of formula (I) wherein R^ is hydrogen may exist in a tautomeric form, as a pyridinol of formula (IA)
JB/LRB/26th February 1991
AP Ο Ο Ο 2 7 1
ΡΑ1137 and such tautomeric forms are included within the present invention.
Compounds of formula (I) which contain an acidic function may form salts with bases and compounds which contain a basic group (e.g. a basic amino group) may form salts with acids. Suitable base salts include inorganic base salts such as alkali metal (e.g. sodium and potassium) salts and alkaline earth metal (e.g. calcium) salts; organic base salts e.g. phenylethylbenzylamine, dibenzylethylenediamine, ethanolamine and diethanolamine salts; and amino acid salts e.g. lysine and arginine. Suitable acid addition salts include those formed from hydrochloric, hydrobromic, nitric, perchloric, sulphuric, citric, tartaric, phosphoric, lactic, benzoic, glutamic, oxalic, aspartic, pyruvic, acetic, succinic, fumaric, maleic, oxaloacetic, isethionic, stearic, phthalic, methanesulphonic, p-toluene sulphonic, benzenesulphonic, lactobionic and glucuronic acids. Most preferably, the salts will be physiologically acceptable.
Physiologically functional derivatives of formula (I) are derivatives which are converted in vivo either by the host or the parasite into a compound of formula (I). Such derivatives include esters and ethers which may be formed for example with the tautomeric pyridinol form (IA). An ester may be formed for example with an alkanoic acid e.g. a alkanoic acid or with a phosphoric acid. Suitable ethers include
C|_g alkyl ethers.
Thus, physiologically functional derivatives according to the invention include those of formula (IB):
R
R (IB)
JB/LRB/26th February 1991
ΡΑ1137 wherein R^, R^, R^ and R4 are as hereinbefore defined and R7 represents a Chalky1 group; a group OC(O)R wherein R represents a
C^alkyl group; or a group -OP(O)(OR^)(OR^), wherein R^ and R10, which may be the same or different, each represent hydrogen or a 7 a q in
Cj_^aIky 1 group. Preferably each of R , R , R and R represent a ^alkyl group eg. methyl or ethyl.
In the compounds of formulae (I), (IA) and (IB)
R1 is preferably a hydrogen atom or a halogen atom, such as chlorine or bromine. Most preferably R^ is a halogen atom.
R is preferably an optionally substituted θ cycloalkyl group, especially an optionally substituted cyclohexyl group, or an optionally substituted aromatic carbocyclic group as defined above, especially an optionally substituted phenyl group. A substituted C-^cyc1oa1ky1 group such as cyclohexyl is preferably substituted by a C| ^alkyl group eg. t-butyl or by a phenyl group, which may be optionally substituted as defined above 2 advantageously by halogen. Most preferably a cyclohexyl group R is substituted at the 4-position with respect to the pyridone ring. A phenyl substituent is preferably substituted at the 3or 4-position with respect to the cyclohexyl ring, advantageously 2 by a halogen atom such as chlorine. When R is a substituted aromatic carbocyclic group such as phenyl this is preferably substituted by one or two halogen atoms, or by a C^alkoxy, halo C|_4alkyl, phenyl, phenoxy, phenylsulphonyl, phenylthio, benzyl, a,α-difluorobenzyl, benzoyl or pyridyloxy group, wherein a phenyl or pyridyl group or moiety in the aforementioned substituents may itself be optionally substituted by one or two substituents selected from halo eg. fluoro, chloro or bromo; haloC^alkyl eg. trifluoromethyl; Cj_4alkoxy eg. methoxy; halo C^alkoxy eg. trifluoromethoxy; or S(0)mCj_4alkyl wherein m is zero, 1 or 2 eg. methylthio, methylsulphinyl or methylsulphonyl.
R^ and R4 each preferably represent a Cj_g alkyl group, especially a
JB/LRB/26th February 1991
AP Ο Ο Ο 2 7 1
ΡΑ1137
C|_4 alkyl group such as methyl or ethyl. r5 is preferably a hydrogen atom.
A particularly preferred group of compounds within general formula (I) is that of formula (IC):
wherein
R1 represents halogen eg. chlorine or bromine;
4
R and R , which may be the same or different each represent a alkyl group;
r5 represents a hydrogen atom;
«·
X represents -0-, -C-, $(0)m, -CH20-, -0CH2-, -CH2S(0)m,
-S(0)mCH2-, -CYZ(CH2)p or -(CH2)pCYZ, or X is a single bond linking the phenyl groups;
Y and Z independently represent hydrogen, halogen or Cj 4 alkyl;
r6 represents halogen, cyano, nitro, amino, mono- or di-(Cj_4) alkylamino, alkyl, halo(C1_4)alky 1, C14 alkoxy, halo(C^_^)aIkoxy; or -S(0)m alkyl;
JB/LRB/26th February 1991
- 8 - ΡΑ1137 η is zero or an integer from 1 to 5 m is zero, one or two; and p is zero or one;
and physiologically acceptable salts and other physiologically functional derivatives thereof.
The group X may be linked to each of the phenyl rings at any unsubstituted position. Similarly the substituent(s) R& may be at any otherwise unsubstituted position of the phenyl ring. Preferably however X is attached to the 4-position with respect to the pyridone group and at least one R^ is at the 3- or 4-position relative to X. Advantageously n is 1 or 2, most preferably 1. X is preferably -0-, -S(0)m, -CYZ, or a single bond.
Most preferably R^ represents a halogen atom (eg. chlorine), CF^, or OCF^ advantageously at the 3- or 4-position relative to X.
Physiologically functional derivatives of compounds (IC) are preferably C^_g alkyl ethers and alkyl and phosphate esters, as defined for formula (IB) hereinabove.
It will be understood that further references herein to compounds of formula (I) include compounds of formulae (IA), (IB) and (IC) unless otherwise indicated.
Specific compounds within the scope of formula (I) include:
3-(4-(4-Chlorophenoxy)pheny1)-2,6-dimethylpyridin-4(lH)-one
3-Chloro-5-(4-(4-chlorophenoxy)phenyl]-2,6-dimethy1pyridin-4(lH)-one
3-[4-(4-Trifluoromethylphenoxy)phenyl]-2,6-dimethy1pyridin-4( 1H)-one
3-(41-Chloro-4-biphenylyl)-2,6-dimethylpyridin-4(lH)-one
3-Bromo-5-(4*-chloro-4-biphenylyl)-2,6-dimethy1pyridin-4(lH)-one
JB/LRB/26th February 1991
AP Ο Ο Ο 2 7 1
ΡΑ1137
3-Chloro-5-(4'-chloro-4-bipheny1yl)-2,6-dimethylpyrid in-4(IH)-one
5-(odo-2,6-dimethyl-3-octylpyridin-4-(lH)-one
5-Cyano-2,6-dimethy1 -3-oc ty1pyrid in-4-(lH)-one
3-( 4-Chlorophenyl )-1,2,6-trimethylpyrid in-4-one
3-Bromo-5-(4-chlorophenyl)-1,2,6-trimethylpyridin-4-one
3-(4-(4-trifluoromethoxyphenoxy)phenyl )-2,6-dimethylpyrid in-4 (IH)-one
3- Bromo-2,6-dimethyl-5-(4-(4-methyl$ulphinylphenoxy)phenyl)pyrid in- <
4- one
3-Bromo-2,6-dimethy1-5-phenylpyrid in-4(IH)-one 3-Chloro-2,6-dimethy 1-5-phenylpyrid in-4 (IH)-one
2.6- Dimethy1-3-(4-chlorophenyl)-pyrid in-4(1H)-one
3-8romo-5-(4-chlorophenyl)-2,6-dimethylpyrid in-4-(IH)-one
3-Chloro-5-(4-chlorophenyl)-2,6-dimethylpyridin-4(1H)-one
3-Bromo-5-(4-fluorophenyl)-2,6-dimethylpyrid-4(IH)-one
3-Chloro-5-(4-fluorophenyl)-2,6-dimethylpyrid in-4(1H)-one
3-Bromo-2,6-dimethyl-5-[4-(trifluoromethyl)phenyl]pyridin-4(lH)-one
5- (3,4-0ichloropheny1)-2,6-dimethylpyrid in-4 (IH)-one
3-8romo-5-(3,4-dichlorophenyl)-2,6-dimethylpyridi n-4(IH)-one 3-Chloro-5-(3,4-dichlorophenyl )-2,6-dimethylpyridin-4(1H)-one 3-(2,4-Di chlorophenyl )-2,6-dimethylpyridin-4(lH)-one
3-Bromo-5-(2,4-dichlorophenyl)-2,6-dimethy 1-pyrid in-4(IH)-one 3-8romo-5-(4-methoxyphenyl)-2,6-dimethylpyrid in-4 (IH)-one 3-(4-8iphenylyl)-2,6-dimethylpyridin-4(lH)-one 3-(4-Biphenyly1)-5-bromo-2,6-dimethylpyridin-4(lH)-one 3-(4*-Fluoro-4-biphenylyl)-2,6-dimethy1-4-pyridone 3-8romo-5-(4'-fluoro-4-biphenylyl)-2,6-dimethylpyrid-4-one 3-Chloro-5-(4'-fluoro-4-biphenylyl)-2,6-dimethylpyrid-4-one
2.6- Dimethyl-3-(4-phenoxyphenyl)pyridin-4(lH)-one
3-Bromo-5-(4-phenoxypheny1)-2,6-dimethylpyridin-4(lH)-one
3-Bromo-5-(4-(4-fluorophenoxy)pheny1]-2,6-dimethylpyrid-4-one
2.6- Dimethyl-3-[4-(3-trifluoromethylphenoxy)phenyl]-4-pyridone 3-[4-(4-Ch loropheny1th io)phenyl]-2,6-dimethylpyrid-4-one 3-Bromo-5-(4-(4-chlorophenylthio)pheny1]-2,6-dimethylpyrid-4-one
3-[4-(4-Ch lorophenylsulphony1)pheny1]-2,6-dimethylpyridin-4-one 3-Bromo-5-[4-(4-chlorophenylsulphonyl)phenyl]-2,6-dimethylpyrid-4-one
J8/LR8/26th February 1991
PA1137
3-Chloro-5-[4-(4-chlorophenylsulphonyl)pheny1]-2,6-dimethylpyrid-4-one 3-(3-(4-Chlorophenoxy)phenyl)-2,6-dimethylpyrid-4-one 3-Bromo-5-[3-(4-chlorophenoxy)pheny1]-2,6-dimethylpyrid-4-one 3-Bromo-5-(3-chloro-4-(4-chlorophenoxy)phenyl)-2,6-dimethylpyrid-4-one 3-Bromo-5-[4-(4-chlorobenzoyl) phenyl]-2,6-dimethylpyrid-4-one 3-Chloro-5-[4-(4-chlorobenzoyl) phenyl]-2,6-dimethylpyrid-4-one
2,6-dimethy1-3-octylpyrid in-4-(1H)-one
3-Bromo-2,6-dime thy 1-5-octylpyr id in-4-( lH)-one
3-Chloro-2,6-dimethyl-5-octylpyridin-4-(lH)-one
3-Cyclohexyl-2,6-dimethylpyridin-4(lH)-one
3-Bromo-5-cyclohexyl-2,6-dimethylpyridin-4(lH)-one
3-CyclohexyImethy1-2,6-dimethylpyrid in-4-(1H)-one
3-Bromo-2,6-dimethy1-5-cyclohexyImethylpyridin-4(lH)-one
Trans-2,6-dimethyl-3-(4-t-butylcyclohexyl)pyridin-4(lH)-one trans-3-Bromo-2,6-dimethy 1-5-(4-t-J)utylcyclohexy1)pyrid in-4(IH)-one 3-[trans-4-(4-Chlorphenyl)cyclohexyl]-2,6-dimethylpyridin-4(lH)-one 3-Bromo-5-[trans-4-(4-chlorophenyl)cyclohexyl]-2,6-dimethylpyridin4(lH)-one trans-3-Chloro-5-[4-(4-chlorophenyl)cyclohexyl]-2,6-dimethy!pyridin4(lH)-one
3- (trans-4-(4-chlorophenvl)cyclohexyImethy1-2,6-dimethylpyridin4- (lH)-one
3-Bromo-l,2,6-trimethy1-5-octylpyridin-4(lH)-one
3-Γtrans-4-(4-Chloroohenvl)cyc1ohexyl)-1,2,6-trimethylpyridin-4-one 3-(4-(3-Trifluoromethoxyphenoxy)pheny1)-2,δ-dimethylpyridin-4(lH)-one 3-Bromo-5-(4-(3-trifluoromethoxyphenoxy)phenyl)-2,6-d imethy1pyridin-4(lH)-one
3-Chloro-5-(4-(3-trifluoromethoxyphenoxy)phenyl )-2,6-dimethylpyridin-4(lH)-one
3- Bromo-2,6-dimethyl-4-methoxy-5-[4-(4-trifluoromethoxyphenoxy) phenyl]pyridine
4- Acetoxy-3-chloro-2,6-dimethy1-5-[4-(4-trifluoromethoxyphenoxy) phenyl]pyridine
3-(4-(4-Chlorophenoxy)phenyl )-l-hydroxy-2,6-dimethylpyridin-4-one
JB/LRB/26th February 1991
PA1137
AP0OO271
3-Bromo-5-(4-(4-chlorophenoxy)phenyl)-1-hydroxy-2,6-dimethylpyridin-4-one
3-8romo-2,6-dimethyl-5-[4-(4-trifluoromethoxyphenoxy)phenyl]-4-pyridinyl diethyl phosphate
Particularly preferred compounds of formula (I) include;
it
3-Bromo-5-[4-(4-chlorophenoxy)phenyl]-2,6-dimethylpyrid in-4 (1H)-one 3-Bromo-5-[4-(4-trifluoromethylphenoxy)phenyl]-2,6-dimethylpyridin4( 1H.)-one
3-Bromo-5-(4-(4-trifluromethoxyphenoxy) phenyl )-2,6-dimethylpyridin4(lH)-one
3-ch1oro-5-(4-(4-trifluoromethoxyphenoxy) phenyl )-2,6-dimethylpyridin4(lH)-one
3-8romo-2,6-dimethyl-5-[4-(3-tri fluoromethylphenoxy)phenyl]-4-pyridone 3-chloro-2,6-dimethyl-5-[4-(3-trifluoromethylphenoxy) phenyl]-4pyridone;
3-chloro-2,6-d imethy1-5-[4-(3-tr i fluoromethoxyphenoxy) phenyl]-4pyridone;
3- bromo-2,6-dimethyl-5-(4-( 3-trifluoromethoxyphenoxy)phenyl]-4pyridone; and
4- acetoxy-3-chloro-2,6-dimethy1-5-[4-(4-trifluoromethoxyphenoxy) phenylJpyridine.
Compounds of formula (I) have been found to exhibit good activity jn vitro against the human malaria parasite Plasmodium falciparum, and also demonstrate good activity in experimental infections with Plasmodium voelii in mice. Compounds of formula (I) have also been found to exhibit activity in vivo in chicks infected with Eimeria tenella and Eimeria maxima, which are both causitive organisms of coccidiosis. In addition activity has been demonstrated against an experimental P.carinii infection in rats. The compounds are thus useful for the treatment and/or prophylaxis of parasitic infections, such as those caused by parasitic protozoa e.g. malaria and those caused by P.carinii. in mammals, including humans.
JB/lRB/26th February 1991 t v onoqA
PA1137
It will be appreciated that the amount of the compound of formula (I) or its salt or other physiologically functional derivative required for use in the treatment or prophylaxis of parasitic infections will depend inter alia on the route of administration, the age and weight of the mammal (e.g. human) to be treated and the nature and severity of the condition being treated. In general, a suitable dose for administration to man is in the range of O.lmg to 200mg per kilogram bodyweight per day, for example from Img/kg to lOOmg/kg, particularly 10 to 40 mg/kg. It will be appreciated that for administration to neonates, lower doses may be required.
For prophylactic treatment the compound of formula (I) or its salt or other physiologically functional derivative may also be given less frequently, e.g. as a single dose on alternate days, once or twice per week or once or twice per month. The dosage for prophylatic treatment will depend inter alia on the frequency of administration, and, where a depot preparation or controlled release formulation is used the rate of release of the active ingredient. Thus for once-weekly administration a suitable prophylactic dose is in the range 0.1 to 100 mg/kg,e.g. 0.5 to 50 mg/kg particularly 5 to 50 mg/kg.
It should be understood that the dosages referred to above are calculated in terms of the compound of formula (1) per se.
The present invention thus further provides a method for the treatment and/or prophylaxis of parasitic infections e.g. parasitic protozoal infections such as malaria or coccidiosis, or infections caused by P.car ini i. in mammals e.g. humans, which comprises administering to a mammal suffering from or susceptible to said infection, with an effective amount of a compound of formula (I) or a physiologically acceptable salt or other physiologically functional derivative thereof.
There is also provided a compound of formula (I) or a physiologically acceptable salt or other physiologically functional derivative thereof
JB/LRB/26th February 1991
PA1137
AP000271 for use in therapy, e.g. in the treatment and/or prophylaxis of parasitic diseases as hereinbefore defined.
The invention also provides the use of a compound of formula (I) or a physiologically acceptable salt or other physiologically functional derivative thereof for the manufacture of a medicament for the treatment and/or prophylaxis of parasitic infections as hereinbefore defined.
For use according to the present invention a compound of formula (I) or a physiologically acceptable salt or other physiologically functional derivative thereof is preferably presented as a therapeutic (ie. pharmaceutical or veterinary) formulation.
Therapeutic formulations comprise an active ingredient (that is, a compound of formula (I) or a physiologically acceptable salt or other pnysiologically functional derivative thereof) together with one or more pharmaceutically or veterinarily acceptable carriers therefor and optionally other therapeutic and/or prophylactic ingredients. The carrier(s) must be acceptable in the sense of being compatible with the other ingredients of the formula and not deleterious to the recipient thereof.
The present invention, therefore, further provides a therapeutic formulation comprising a compound of formula (I) or a physiologically acceptable salt or physiologically functional derivative thereof together with a pharmaceutically or veterinarily acceptable carrier therefor.
There is also provided a method for the preparation of a therapeutic formulation comprising bringing into association a compound of formula (I) or a physiologically acceptable salt or physiologically functional derivative thereof, and a pharmaceutically or veterinarily acceptable carrier therefor.
J8/LR8/26th February 1991
PA1137 !} ri
HA
The compound of formula (I) or its salt or other physiologically functional derivative may conveniently be presented as a therapeutic formulation in unit dosage form. A convenient unit dose formulation contains the active ingredient in an amount of from 10 mg to lg.
Therapeutic formulations include those suitable for oral, topical (including dermal, buccal and sublingual), rectal and parenteral (including subcutaneous, intradermal, intramuscular and intravenous) administration. The formulation may, where appropriate, be conveniently presented in discrete dosage units and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing into association the compound of formula (I) or a physiologically acceptable salt or other physiologically functional derivative thereof with liquid carriers or finely divided solid carriers or both and then, if necessary, shaping the product into the desired formulation.
Therapeutic formulations suitable for oral administration wherein the carrier is a solid are most preferably presented as unit dose formulations such as boluses, capsules or tablets each containing a predetermined amount of the active ingredient. A tablet may be made by compression or moulding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules optionally mixed with a binder, lubricant, inert diluent, lubricating agent, surface-active agent or dispersing agent. Moulded tablets may be made by moulding an active ingredient with an inert liquid diluent. Tablets may be optionally coated and, if uncoated, may optionally be scored. Capsules may be prepared by filling the active ingredient, either alone or in admixture with one or more accessory ingredients, into the capsule shells and then sealing them in the usual manner. Cachets are analogous to capsules wherein the active ingredient together with any accessory ingredient(s) is sealed in a rice paper envelope. A compound of formula (I) or a physiologically acceptable salt or other
JB/LRB/26th February 1991
ΡΑ1137
AP Ο Ο Ο 2 7 1 physiologically functional derivative thereof may also be formulated as dispersible granules, which may for example be suspended in water before administration, or sprinkled on food. The granules may be packaged e.g. in a sachet. Formulations suitable for oral administration wherein the carrier is a liquid may be presented as a solution or a suspension in an aqueous liquid or a non-aqueous liquid, or as an oil-in-water liquid emulsion. »
Formulations for oral administration include controlled release dosage forms e.g. tablets wherein the active ingredient is formulated in an appropriate release - controlling matrix, or is coated with a suitable release - controlling film. Such formulations may be particularly convenient for prophylactic use.
Therapeutic formulations suitable for rectal administration wherein the carrier is a solid are most preferably presented as unit dose suppositories. Suitable carriers include cocoa butter and other materials commonly used in the art. The suppositories may be conveniently formed by admixture of the active ingredient with the softened or melted carrier(s) followed by chilling and shaping in moulds.
Therapeutic formulations suitable for parenteral administration include sterile solutions or suspensions of the active ingredient in aqueous or oleaginous vehicles. Injectible preparations may be adapted for bolus injection or continuous infusion. Such preparations are conveniently presented in unit dose or multi-dose containers whidh are sealed after introduction of the formulation until required for use. Alternatively, the active ingredient may be in powder form which is constituted with a suitable vehicle, such as sterile, pyrogen-free water, before use.
The compound of formula (I) or a physiologically acceptable salt or other physiologically functional derivative thereof may also be formulated as a long-acting depot preparation, which may be
JB/lRB/26th February 1991
- 16 PA1137 administered by intramuscular injection or by implantation e.g. subcutaneously or intramuscularly.Depot preparations may include, for example, suitable polymeric or hydrophobic materials, or ion-exchange resins. Such long-acting formulations are particularly convenient for prophylactic use.
It should be understood that in addition to the aforementioned carrier ingredients the therapeutic formulations for the various routes of administration described above may include, as appropriate one or more additional carrier ingredients such as diluents, buffers, flavouring agents, binders, surface active agents, thickeners, lubricants, preservatives (including anti-oxidants) and the like, and substances included for the purpose of rendering the formulation isotonic with the blood of the intended recipient.
The compounds of the present invention may be administered in combination or concurrently with other therapeutic agents, for example other antimalarial agents, such as chloroquine, mefloquine, quinine, artemesinin, halofantrine, pyrimethamine, or hydroxynaphthoquinones such as those described in European Patent Application No. 123238; anticoccidial agents such as monensin, halofuginone, arprinocid, amprolium, dinitolmide, robenidine or salinomycin; or antibiotics such as clindamycin, tetracycline or doxycycline. In particular, compounds of formula (I) have been found to potentiate the activity of hydroxynaphthoquinones eg. those described in European Patent
Application No. 123238, such as 2-[4-(4-Chlorophenyl)cyclohexyl-3hydroxy-1,4-naphthoquinone, against P.falciparum and P.carinii. In a further aspect therefore, the present invention provides synergistic compositions comprising a compound of formula (I) and a hydroxynaphthoquinone.
When compounds of formula (I) are used in combination with a second therapeutic agent the dose of each compound will vary from that required when the compound is used alone. Appropriate dosages can be readily determined by those skilled in the art.
JB/LRB/26th February 1991
ΡΑ1137
AP Ο Ο Ο 2 7 1
Formulations suitable for veterinary use include those adapted for oral, parenteral, and intrarumena1 administration.
Veterinary formulations suitable for oral administration include drenches (oral liquid dosing), which may be solutions or suspensions; tablets, boluses, pastes, or in-feed preparations in the form of powders, granules or pellets.
Alternatively, veterinary formulations may be adapted to be administered parenterally by sub-cutaneous, intramuscular or intravenous injection of a sterile solution or suspension, by implantation or as an intramammary injection whereby a suspension or solution is introduced into the udder via the teat.
For intrarumenal injection, the compounds of the invention may be formulated as solutions or solid or micocapusule suspenses. Typically the formulations are similar to the oral liquid preparations or parenteral preparations described herein. Such formulations are injected directly into the rumen, usually through the side of the animal, for example by a hypodermic syringe and needle or by an automatic injection device capable of giving single or multiple doses.
For veterinary administration a compound of formula (I) or its salt or other physiologically functional derivative is preferably formulated with one or more veterinarily acceptable carriers.
For oral administration, fine powders or granules may contain dieting agents, for example lactose, calcium carbonate, calcium phospnate, mineral carriers, etc., dispersing and/or surface active agents, for example polysorbates such as Tweens or Spans, and may be presented in a drench, in water or in a syrup, in a bolus, paste, or in a 'eed preparation, in capsules or sachets in the dry state or -n a non-aqueous suspension, or in a suspension in water or syrup. «here desirable or necessary, preserving, suspending, thickening or emulsifying agents can be included. If intended for oral use, a bolus
BAD original
JB/LR8/26th February 1991 « i < ν ύύΊμ
- 18 - ΡΑ1137 will be provided with retention means to inhibit regurgitation, for example it may be weighted with a heavy density material such as iron or tungsten or the like or may be retained by its shape, for example by wings which spring after administration. Boluses may contain disintegrating agents such as maize starch or calcium or sodium methyl celluloses, hydroxypropylmethylcellulose, guar based vegetable gums, sodium alginates or sodium starch glycolates; granulating or binding agents such as starch in the form of mucilage, starch derivatives, such as Snow Flake, cellulose derivatives such as talc, calcium stearate, methyl cellulose, gelatin or polyvinylpyrrolidone; and/or lubricating agents, such as magnesium stearate or stearic acid.
For parenteral administration, the compounds may be presented in sterile injection solutions which may contain antioxidants or buffers, or as injectable suspensions. Suitable solvents include water, in the case of suspensions, and organic solvents such as dimethylformamide, dimethylacetamide, diethylacetamide, ethyl lactate, ethyl akate, dimethylsulphoxide, alcohols, e.g. ethanol, glycols, e.g. ethylene glycol, propylene glycol, butylene glycol and hexamethylene glycol, polyethylene glycols containing 2 to 159 ethylene glycol monomer units and having average molecular weights from about 90 to 7500, glycerin formal, glycofural, glyerol, isopropylmyristate N-methylpyrrolidone,
2-pyrrolidone polyethylene glycoethers of tetrahydrofurfuryl alcohol and diethylene glycol, and fixed and neutral oils, for example fractionated coconut oil. Parenteral formulations may also contain isotonic agents.
For veterinary use a compound of formula (I) may be employed together with other therapeutic agents used in the field of animal health, for example with anticoccidial and/or antitheilerial agents
According to a further aspect of the present invention there is also provided a process for the preparation of compounds of formula (I) and physiologically acceptable salts and other physiologically functional derivatives thereof, which comprises
JB/LRB/26th February 1991
PA1137
APOOO 27 1 (A) to prepare a compound of formula (I) wherein R1 represents a hydrogen atom the reaction of a compound of formula (II)
with ammonia or a derivative thereof.
(8) to prepare a compound of formula (I) wherein R^ is a halogen atom, the reaction of a compound of formula (I) wherein R^ is hydrogen with a halogenating agent;
(C) to prepare a compound of formula (I) wherein R^ is a cyano group, the reaction of a compound of formula (I) wherein R^ is iodine, with a metal nitrile;
(D) to prepare a compound of formula (IB), the reaction of a compound of formula (I) with an alkylating, acylating or phosphorylating agent.
Process (A) may be effected using a compound H9NR^. Thus, for example aqueous ammoma may be used to prepare a compound wherein R is hydrogen. To prepare a compound where R^ is other than hydrogen, the appropriate optionally substituted alkylamine derivative may be employed eg. methylamine or hydroxyl amine. The reaction may be conveniently carried out at a temperature in the range of 100 to
175°C. The reaction may be effected in a water miscible organic solvent, for example an alcohol such as ethanol.
Halogenating agents which may be employed in process (B) include N-halosuccinimide e.g. N-chloro- or N-bromo-succin imide, bromine,
JB/LRB/26th February 1991
PA1137 v I’ «ΙΑ phosphorus pentachloride, thionyl chloride or bromide or oxalyl chloride. Solvents which may be employed include acetic acid, water and halogenated solvents eg. dichloromethane. The reaction may conveniently be effected at a temperature in the range 0° to 100°C.
A preferred metal nitrile for use in Process (C) is cuprous cyanide. The reaction may be effected in a polar solvent, such as Ν,Ν-dimethylformamide or an alcohol. Conveniently the reaction temperature is in the range 15° to 200°C.
Alkylation according to Process (D) may be effected by methods well known in the art, using for example an alkylating agent such as the corresponding alkyl halide or dialkylsulphate, eg. methyl iodide or dimethylsulphate. The alkylation is conveniently carried out in the presence of a base, to generate_ the required pyridinol carbanion. Bases which may be employed include alkali metal and alkaline earth metal carbonates and alkoxides eg. potassium carbonate or potassium t-butoxide. Acylation or phosphorylation may be effected using the appropriate acid or a corresponding acylating or phosphorylating agent. Acylating agents which may be employed include acid halides eg. acid chlorides, eg. acetyl chloride; acid anhydrides; and activated esters. Phosphorylating agents include phosphorus oxyhalides; phosphoric acid esters eg. a mono-,di-or tri-(Cj_g alkyl) phosphate such as diethylchlorophosphate; and phosphoric acid anhydrides. Alkylation, acylation and phosphorylation may conveniently be effected in the presence of a solvent such as dimethylformamide, and at a non-extreme temperature, for example in the range 0 to 100°C.
The compounds of formula (II) may be prepared by reaction of a compound of formula (III):
? 2
H3C-C-CH2ir (III)
J8/LRB/26th February 1991
AP Ο Ο Ο 2 7 1
ΡΑΙ 137 with an acid anhydride of formula (IV)
0
R3-£-O-(?-R4 (IV)
The compound (IV) may be a mixed anhydride, or, where R3 and R4 are the same, a symmetrical anhydride. Alternatively, to prepare 3 4 compounds wherein R and R are the same, the corresponding acid may be used. The reaction is advantageously carried out in the presence of polyphosporic acid, and at elevated temperature, e.g. in the range 50 to 120°C.
Compounds of formula (III) may be prepared by various methods known in the art for preparing analogous compounds, which methods include:
(i) reduction of the corresponding nitropropene derivative of formula (V):
(V) for example using the method described by F.A. Ramirez and A. Burger (J.Am.Chem.Soc. vol 72, 2781, 1950);
(ii) to prepare compounds of formula (III) wherein R is an aryl group, reaction with potassium acetylacetonate in the presence of cuprous iodide, followed by deacetylation of the initial
3-diketone product under alkaline conditions, according to the following reaction scheme:
R28r +*kCH(COCH3)2—) (R2CH(COCH3)?]—>R2CH2'icH3 (III)
Cul
OHJ8/LRB/26th February 1991
- 22 PA1137 ο HA (see S. Sugai, et al., Chem Letts. 597 1982) (iii) the palladium - catalysed coupling of a tin enolate, generated jn, situ from isopropenyl acetate and tri-n-butyltin methoxide, as shown in the following scheme:
ococh3 0
R28r + H2C=C-CH3 -R2CH2CCH3 (HI)
Bu3SnOMe
Pd[(o-to1y1kP]2Cl2 Toluene, IOCTC (see M. Kosugi et al, Bull Chem Soc. Japan, vol 57, 242, 1984).
(iv) Reaction of the corresponding carboxylic acid R CH2C00H with lithium hydride, followed by methyl lithium; and (v) Reaction of the bromide R CH2Br with magnesium to form a Grignard reagent which is then reacted with acetic anhydride to form a compound of formula (III).
Compounds of formula (V) may themselves be prepared by reaction of the corresponding aldehyde of formula (VI):
R2CHO (VI) with nitroethane.
The invention will now be illustrated by the following non-limiting examples.
The following abbreviations are used in the preparations and examples:
J8/LR8/26th February 1991
PA1137
APO 00 2 7 1
- 23 DMF - N,N-dimethylformamide.
OMSO - dimethylsulphoxide.
DME - 1,2-dimethoxyethane.
All temperatures are in degrees Celsius (°C).
Preparation of Intermediates
Preparation 1
4-(4-Chlorophenoxy)benzaIdehvde
4-Chlorophenol (22.6g) was added to a stirred solution of sodium methoxide (9.5g) in methanol (80ml). After 30min the solvent was evaporated in vacuo. Residual traces of methanol were removed by addition of toluene and evaporating again in vacuo. The residue was taken up in DMF(200ml) and 4-fluorobenzaldehyde (19.85g) added. The mixture was stirred and heated at 120° for 4 hr, cooled, poured into water and extracted with toluene (2x200ml). The combined extracts were washed with water, 2M sodi-um hydroxide and satd. brine, dried over magnesium sulphate and concentrated to leave a brown oil. Distillation gave the title compound (26.03g), b.p. = 140-50°/0.5mm.
The following compounds were prepared from the appropriate phenols by the general procedure described for preparation 1:
(a) 4-(3-Chlorophenoxy)benzaldehyde.
(b) 4-(3-Tr i f1uoromethy1phenoxy)benza1dehyde.
(c) 4-(4-Fluorophenoxy)benzaldehyde, m.p. 74-77°.
(d) 4-(4-Methoxyphenoxy)benzaldehyde, m.p. 48-50°.
(e) 4-(4-Methylthiophenoxy)benzaldehyde.
JB/LRB/26th February 1991
- 24 PA1137
MA (f) 4-(3,4-Dichlorophenoxy)benzaldehyde.
(g) 4-(3,5-Dichlorophenoxy)benzaldehyde.
(h) 4-(2,4-Dichlorophenoxy)benzaldehyde.
(i) 4-(4-Chlorophenylthio)benzaldehyde, m.p. 82-84°.
(j) 4-(4-Trifluoromethoxyphenoxy)benzaldehyde, b.p. 13O-135°/O.5mm, NMR 5H (CDC13) 9.86 (IH, s), 8.0-7.7 (2H, m), 7.5-6.9 (6H, m).
(k) 4-(3-Trifluoromethoxyphenoxy)benzaldehyde. NMR $H (CDCl^) 9.9(1H,S); 7.95 - 7.75 (2H,m); 7.4 - 6.9 (6H,m).
Preparation 2
4-(4-Chlorophenoxy)phenylpropan-2-one
A mixture of 4-(4-chlorophenoxy)benzaldehyde (256g) and butylamine (239ml) in toluene (1 litre) was heated to reflux and the water formed removed through a Dean & Stark head. After 2 hr the mixture was concentrated in vacuo and the residue dissolved in acetic acid (750 ml) and nitroethane (118.5ml), heated at 100° for 2 hr, cooled and poured into iced water. The yellow solid was filtered, dried in air and recyrstallised from ethanol (750ml) to afford 4-(4-chlorophenoxy)phenyl-2-nitropropene (254.7g), m.p. 69-71°. Acetic acid (115ml) was added over 30 min to a well stirred, refluxing mixture of the
4-(4-chlorophenoxy)phenyl-2-nitropropene (28.9g), iron powder (56g), water (20ml) and methanol (150ml). After 3 hr it was cooled and partitioned between water (500ml) and dichloromethane (200ml). The organic phase was filtered, washed with water and satd. aq. sodium bicarbonate, dried over magnesium sulphate and concentrated j_n vacuo to leave a yellow oil. Trituration with hexane afforded the title compound as fine colourless crystals (14.6g), m.p. 50-52°.
JB/LRB/26th February 1991
AP Ο Ο Ο 2 7 1
- 25 PAH37
The following compounds were prepared from the appropriate aldehyde by the general procedure described for preparation 2:
(a) 4-(3-Chlorophenoxy)phenylpropan-2-one, NMR 5H (CDC1j) 7.45-6.6 (8H, m), 3.6 (2H, s), 2.1 (3H, s).
(b) 4-(3-Trifluoromethylphenoxy)phenylpropan-2-one, NMR 5H (CDClj)
7.4-6.7 (8H, m), 3.6 (2H, s), 2.1 (3H, s).
(c) 4-(4-Fluorophenoxy)pheny1propan-2-one, m.p. 51-54°, NMR iH (CDC13) 7.3-6.7 (7H, m), 3.64 (2H, s), 2.15 (3H, s).
(d) 4-(4-Methoxyphenoxy)phenylpropan-2-one, NMR 5H (CDCl^) 7.3-6.6 (7H, m),3.7 (3H, s), 3.6 (2H, s), 2.1 (3H, s).
(e) 4-(4-Methylthiophenoxy)phenylpropan-2-one, NMR 5H (CDCl^) 7.4-6.7 (8H, m), 3.64 (2H, s), 2.45 (3H, s), 2.15 (3H, s).
(f) 4-(3,4-Dichlorophenoxy)phenylpropan-2-one, m.p. 78-80°, NMR 5H (COC13) 7.4-6.65 (7H, m), 3.65 (2H, s), 2.1 (3H, s).
(9) 4-(3,5-Dichlorophenoxy)pheny1propan-2-one.
(h) 4-(2,4-0ichlorophenoxy)phenylpropan-2-one, NMR 5H (CDCip 7.3-6.3 (7H, m), 3.55 (2H, s), 2.1 (3H, s).
μ· (i) 4-(4-Chlorophenylthio)pheny1propan-2-one.
(j) 4-(4-Trifluoromethoxyphenoxy)phenylpropan-2-one, m.p. 57-53°, NMR 5H (CDC13) 7.4-6.85 (8H, m), 3.7 (2H, s), 2.2 (3H, s).
(k) 4-(3-Trifluoromethoxyphenoxy)phenylpropan-2-one NMR 5H (COCip
7.3-6.7 (8H,m); 3.6(2H,s); 2.l(3H,s).
Preparation 3
JB/LRB/26th February 1991 • 26 PA1137
4-(4-Chiorophenyl) phenylpropan-2-one
To a stirred solution of 4-bromo-41-chlorobiphenyl (16g; F.R. Shaw and
E.E. Turner. J.Chem.Soc., 285 (1932) ), isopropenyl acetate (9g) and dichlorobis(tri-o-tolylphosphine)palladium (0.47g) in dry toluene (30ml), under nitrogen, was added tributyltin methoxide (25.9ml; Aldrich). The mixture was stirred and heated at 100° for 5hr, cooled and the solvent evaporated in vacuo. The residue was chromatographed on silica gel, eluting with cyclohexane then ether. The resultant solid was recrystal 1ised from cyclohexane to afford the title compound (lOg), m.p. 79-81°.
The following compounds were prepared from the appropriate bromo derivatives by the general procedure described for preparation 3:
(a) 4-Biphenylylpropan-2-one, NMR 5H (CDClj) 7.7-7 (9H, m), 3.65 (2H, s), 2.1 (3H, s). (From 4-bromobiphenyl -Aldrich).
(b) 4'-Fluoro-4-biphenylylpropan-2-one, m.p. 68-70°, NMR <SH (CDCl^) 7.8-7.7.0 (8H, m), 3.76 (2H, s), 2.2 (3H, s). (From 4-bromo-4'fluorobiphenyl prepared by the bromination of 41-fluorobiphenyl following the procedure of F.R. Shaw and E.E. Turner, J. Chem. Soc., 285, 1932).
(c) 3-(4-Chlorophenoxy)phenylpropan-2-one.
(d) 4-(5-Trifluormethylpyrid-2yloxy)phenylpropan-2-one, m.p. 58-61°, NMR SH (CDCip. (From 2-(4-bromophenoxy)-5-trifluoromethylpyridine, prepared by the reaction of the sodium salt of 4-bromophenol with 2-chloro-5-trifluoromethylpyridine).
(e) 4-(4-Chlorophenylsulphonyl)phenylpropan-2-one, NMR SH (CDCip
8.1-7.1 (8H, m), 3.72 (2H, s), 2.1 (3H, s). (From 4-bromo-4'chlorodiphenylsulphone, L.G. Groves and E.E. Turner, J. Chem. Soc., 509, 1928).
JB/LRB/26th February 1991
AP Ο 00 2 7 1
- 27 - PA1137 (f) 4-(4-Chlorophenacyl)phenylpropan-2-one, m.p. 98-100°. (From 4bromo-4'-chlorobenzophenone, L.G. Groves and E.E. Turner, J. Chem. Soc., 509, 1928).
(g) 4-(4-Chlorobenzy1)pheny1propan-2-one, NMR sH (CDCl-j) 7.3-6.8 (8rf, m), 3.76 (2H, s), 3.5 (2H, s), 1.98 (3H, s). (From 4-bromo-(4chlorophenyl)methylbenzene, m.p. 58-59°, prepared by the reduction of 4-bromo-4‘-chlorobenzophenone with sodium borohydride in trifluoroacetic acid, following the procedure of G.W. Gribble, W.J. Kelly and S.E. Emery, Synthesis, 763, 1978).
(h) 4-(4-Chlorodifluorobenzyl)phenylpropan-2-one, m.p. 90-93°, NMR (CDCip 7.8-6.85 (8H, m), 3.75 (2H, s), 2.15 (3H, s). From 4bromo-(4-chlorophenyl)difluoromethylbenzene, m.p. 55-57°. (Prepared from 4-bromo-4‘-chlorobenzophenone following the procedure of H. Volz and W.O. Mayer, Ann. Chem., 1407, 1981).
(i) 3-Chloro-4-(4-chlorophenoxy)phenylpropan-2-one, NMR SH (CDC1^)
7.5-6.8 (7H, m), 3.7 (2H, s), 2.24 (3H, s). (From 4bromo-2,4'-dichlorodiphenyl ether prepared from 4-amino-2,4'dichlorodiphenyl ether).
Preparation 4
4-bromo-4l-trifluoromethvidiphenylether
To a solution of 4-bromophenol (86.5g) in OMSO (1.25 litres) was added potassium t-butoxide (56g) and 4-chlorobenzotrifluoride (90£; Aldrich). The mixture was stirred and heated at 160° for 3 days, cooled, poured into iced water and extracted with toluene (3x400ml). The combined extracts were washed with 2N sodium hydroxide and water, dried over magnesium sulphate and concentrated to leave an oil. Distillation afforded the title compound (133.6g), b.p.=94-96°/0.15mm.
Preparation 5
JB/LRB/26th February 1991
- 28 ΡΑ1137
4-(4-TrifluoromethylphenoxyIphenylpropan-2-one
To a stirred solution of 4-bromo-4'-trifluoromethyldiphenylether (53.9g) in DMF (1 litre) was added cuprous iodide (32.4g) and potassium acetylacetonate hemihydrate (125g; Aldrich). The mixture was stirred and heated at 100° for 24 hr, cooled, stirred with 2M sodium hydroxide (250 ml) for 1 hr and extracted with toluene (2x500ml). The combined extracts were washed with water, 1M hdrochloric acid and satd. aq. sodium bicarbonate, dried over magnesium sulphate and concentrated in vacuo to leave a dark brown oil. Trituration with 1:1 ether/hexane followed by recrystallisation from hexane afforded the title compound as colourless crystals (32.lg), m.p. 88-90°, Nmr <$H (COC13) 5.5-7.8 (8H, m), 3.62 (2H, s), 2.18 (3H, s).
Preparation 6 trans-(4-t-Butylcyclohexyl)propan-2-one
A solution of trans-(4-t-butylcyclohexyl)acetic acid (9.96g) in dry DME (30 ml) was added over 10 min to a vigorously stirred suspension of powdered lithium hydride (0.5g) in dry DME (30 ml). The mixture was refluxed for 2.5 hr, cooled on ice and a solution of methyl lithium in ether (63 m1;1.6M solution) added over 30 min. The mixture was then stirred at room temperature for 2 hr, and poured into a mixture of cone, hydrochloric acid (13.5 ml) and water (200 ml). The organic phase was separated and the residue extracted with ether. The extracts were combined, washed with aq. sodium carbonate and satd. brine, dried over magnesium sulphate and concentrated jn vacuo. Distillation afforded the title compound (7.7g), b.p. 90-100°/0.3mm, NMR 5H (COC13) 2.28 (2H, d, J 7Hz), 2.12 (3H, s), 1.85-1.65 (6H, m), 1.05-0.85 (4H, m), 0.85 (9H, s).
Preparation 7 trans-(4-(4-Chloropheny1)cyclohexyl)propan-2-one
JB/LRB/26th February 1991
AP Ο Ο Ο 2 7 1
- 29 ΡΑΙ’37
To a stirred suspension of trans-(4-(4-chloropheny!)cyclohexane)carboxylic acid (47.74g) in dry ether (250 ml), under nitrogen, was added dropwise borane-methyl sulphide complex (8 ml; ca.IOM solution Aldrich). After 30 min the mixture was heated to reflux and further borane-methyl sulphide complex (16 ml) added. After I hr the mixture was cooled to room temperature and poured into methanol (500 ml). The solvent was evaporated in vacuo and the residue treated again with methanol (100 ml) followed by concentration in vacuo, to give trans-(4-(4-chlorophenyl)cyc1ohexyl) methanol (44g), m.p. 60-63°. A portion of this alcohol (41g) was added to 48% hydrobromic acid (61g) and cone, sulphuric acid (20g). The mixture was stirred and heated at 140° for 5.5 hr, cooled and poured into iced water. The precipitate was filtered, dissolved in ether, washed with satd. aq. sodium bicarbonate and brine, dried over magnesium sulphate and the solvent evaporated jin vacuo to leave a brown oil. Trituration with cold hexane gave trans-(4-(4-chlorophenyl)cyclohexyl)methyl bromide (44g),
m.p. 36-38°. To magnesium turnings (33.06g) in dry ether (70ml) under nitrogen was added a crystal of iodine followed by a solution of trie bromide (19.7g) in ether (20ml). The mixture was heated at reflux for a further 30 min, cooled to room temperature and then added drcpw'se to vigorously stirred acetic anhydride in dry ether (70ml) at -78°, such that the temperature did not exceed -70°. The mixture «as stirred at -78° for a further 1 hr, then allowed to warm to 0° and poured into satd. aq. ammonium chloride (200ml). The mixture «as stirred for 30 min then the organic phase was separated and «ashed with satd. aq. sodium bicarbonate and brine, dried over magnesium sulphate and concentrated in vacuo, to leave a white solid , «hich «as recrystal 1ised from hexane to afford the title compound (9.3g), m.p. 58-50°, NMR 5H (COCl^ 7.3-7.0 (4H, m), 2.55-2.3 (IH, m), 2.4-2.3 (2H. m), 2.15 (3H, s), 2-1.75 (5H, m), 1.6-1.45 (2H, m), 1.25-1.0 (2H, m).
Preparation 8
3-(4-(4.Chlorophenoxy)phenyl )-2,6-dimethylpyran-4-one
J8/LRB/26th February 1991
PA1137
AP000271
- 30 A solution of 4-(4-chlorophenoxy)pheny1propan-2-one (26g) in acetic anhydride (100ml) was added, over 5 min, to a vigorously stirred mixture of polyphosphoric acid (200g) and acetic anhydride (100ml) at 80°. After stirring for 30 min the mixture was poured into water (1 litre) and extracted with toluene (2 x 500 ml). The combined extracts were washed with water then satd. aq. sodium bicarbonate, dried over magnesium sulphate and evaporated to give an oil. Trituration with ether gave a yellow solid, which was recrystallised from carbon tetrachloride to afford the title compound (14.64g), m.p. 150-152°, NMR δΗ (COC13) 6.95-7.4 (8H, m), 6.2 (IH, s), 2.3 (3H, s), 2.2 (3H, s).
The following compounds were prepared from the appropriate substituted ketones by the general procedure described for preparation 3:
(a) 3-0ctyl-2,6-dimethylpyran-4-one, NMR δΗ (CDCl^) 5.95 (IH, s), 2.25 (3H, s), 2.2 (3H, s), 2.4-1.9 (2H, m), 1.6-0.8 (15H, m). (From 2-undecanone - Aldrich).
(b) 3-Cyclohexyl-2,6-dimethylpyran-4-one, NMR δΗ (COCl^) 5.95 (IH, s), 2.3 (3H, s), 2.15 (3H, s), 2-0.9 (11H, m). (From cyclohexylacetone - Lancaster Synthesis).
(c) 3-CyclohexyImethy1-2,6-dimethylpyran-4-one.
(d) 3-trans-(4-t-Butylcyclohexyl)-2,6-dimethylpyran-4-one, NMR δΗ (COC13) 5.9 (IH, s), 2.28 (3H, s), 2.15 (3H, s), 0.85 (9H, s),
2.7- 0.8 (10H, m).
(e) 3-trans-(4-(4-Chlorophenyl)cyclohexy1)-2,6-dimethylpyran-4-one, m.p. 148-150°, NMR δΗ (CDCl-j) 7.3-7.1 (4H, m), 6.0 (IH, s),
2.8- 2.5 (2H, m), 2.4-2.15 (2H, m), 2.32 (3H, s), 2.18 (3H, s),
2-1.85 (2H, m), 1.7-1.35 (4H, m).
JB/LRB/26th February 1991
AP Ο Ο Ο 2 7 1
- 31 - ΡΑ1137 (f) 3-Phenyl-2,6-dimethy1pyran-4-one, m.p. 70-75°. (Previously reported by R.L. Letsinger and J.D. Jamison, J. Org. Chem., 193, 1961).
(g) 3-(4-Chlorophenyl)-2,6-dimethylpyran-4-one, m.p. 93-95°, NMR δΗ (CDC13) 7.4-6.9 (4H, m), 6.1 (1H, s), 2.3 (3H, s), 2.2 (3H, s).
(h) 3-(3,4-0ichlorophenyl)-2,6-dimethylpyran-4-one, m.p. 132-136°,
NMR δΗ (CDC13) 7.48 (1H, d, J 9Hz), 7.33 (1H, d, J 1.5Hz), 7.08 (1H, dd, J 9, 1.5Hz), 6.19 (1H, s), 2.28 (3H, s), 2.2 (3H, s).
(i) 3-(2,4-0ichlorophenyl)-2,6-dimethylpyran-4-one, NMR δΗ (CDCl^)
7.45 (1H, m), 7.3-7.0 (2H, m), 6.15 (1H, s), 2.3 (3H, s), 2.1 (3H, s).
(j) 3-(4-Trifluoromethylphenyl)-2,6-dimethylpyran-4-one, m.p.
120-123°, NMR δΗ (CDCl-j) 7.68 (2H, m), 7.38 (2H, m), 6.22 (1H,
s), 2.29 (3H, s), 2.18 (3H, s).
(k) 3-(4-Fluorophenyl)-2,6-dimethylpyran-4-one, m.p. 116-118°, NMR δΗ (CDC13) 7.3-7.0 (4H, m), 6.2 (1H, s), 2.28 (3H, s).
(l) 3-(4-Methoxyphenyl)-2,6-dimethylpyran-4-one, m.p. 97-99°, NMR δΗ (COC13) 7.05 (4H, m), 6.18 (1H, s), 3.78 (3H, s), 2.28 (3H, s),
2.15 (3H, s).
(m) 3-(4-(3-Chlorophenoxy)phenyl)-2,6-dimethylpyran-4-one, NMR δΗ (C0C13) 7.35-6.75 (8H, m), 6.15 (1H, s), 2.25 (3H, s), 2.2 (3H,
s).
(n) 2,6-0imethy1-3-(4-(3-trifluormethylphenoxy)phenyl)pyran-4-one,
NMR δΗ (CDC13) 7.45-6.85 (8H, m), 6.15 (1H, s), 2.25 (3H, s),
2.15 (3H, s).
JB/LRB/26th February 1991
- 32 - ΡΑ1137 (ο) 3-(4-(4-Fluorophenoxy)pheny])-2,6-dimethylpyran-4-one, NMR SH (CDC13) 7.3-7.1 (2Η, m), 7.1-6.9 (6H, m), 6.2 (IH, s), 2.28 (3H,
s), 2.2 (3H, s).
(p) 3-(4-(4AMethoxyphenoxy)phenyl)-2,6-dimethylpyran-4-one, NMR SH (CDC13) 7.2-6.6 (8H, m), 6.1 (IH, s), 3.8 (3H, s), 2.3 (3H, s),
2.2 (3H, s).
(q) 2,6-Dimethyl-3-(4-(4-methylthiophenoxy)phenyl)pyran-4-one, NMR sH (CDC13) 7.35-7.1 (4H, m), 7.1-6.9 (4H, m), 6.2 (IH, s), 2.48 (3H. s), 2.28 (3H, s), 2.2 (3H, s).
(r) 3-(4-(3,4-Dichlorohenoxy)phenyl)-2,6-dimethylpyran-4-one, NMR SH (CDC13) 7.55-6.8 (7H, m), 6.25 (IH, s), 2.3 (3H, s), 2.2 (3H, s).
(s) 3-(4-(3,5-Dich1orophenoxy)pheny1)-2,6-dimethylpyran-4-one.
(t) 3-(4-(2,4-Dichlorophenoxy)phenyl)-2,6-dimethylpyran-4-one, NMR 5H (CDC13) 7.5-6.6 (7H, m), 6.15 (IH, s), 2.25 (3H, s), 2.2 (3H, s).
(u) 3-(4-(4-Chlorophenylthio)phenyl)-2,6-dimethylpyran-4-one, NMR SH (CDC13) 7.5-7.0 (8H, m), 6.2 (IH, s), 2.24 (3H, s), 2.16 (3H, s).
(v) 3-(4-Biphenyly1)-2,6-dimethylpyran-4-one, m.p. 188-190°, NMR sH (dg-DMSO) 8.1-7.3 (9H, m), 6.4 (IH, s), 2.6 (3H, s), 2.5 (3H, s).
(w) 3-(4'-Fluoro-4-biphenylyl)-2,6-dimethylpyran-4-one, NMR sH (dg-OMSO) 7.8-7.65 (4H, m), 7.4-7.25 (4H, m), 6.22 (IH, s), 2.3 (3H, s), 2.2 (3H, s).
(x) 3-(3-(4-Ch1orophenoxy)phenyl)-2,6-dimethylpyran-4-one, m.p.
114-116°, NMR SH (dg-OMSO) 7.45-7.2 (3H, m), 7.1-6.8 (5H, m). 6.2 (IH, s), 2.28 (3H, s), 2.2 (3H, s).
(y) 2,6-0imethyl-3-(4-(5-trifluormethylpyrid-2yloxy)phenyl)pyran-4JB/LRB/26th February 1991
AP Ο Ο Ο 2 7 1
ΡΑ1137 one, NMR SH (COCl-j) 8.45 (IH, s), 7.9 (IH, d, J 9Hz), 7.25 (4H,
m), 7.0 (IH, d, J 9Hz), 6.2 (IH, s), 2.28 (3H, s), 2.24 (3H, s).
(ai) 3-(4-(4-Chlorophenylsu1 phony 1)pheny1)-2,6-dimethylpyran-4-ons, m.p. 183-185°, NMR SH (CDCip 8.0-7.85 (4H, m), 7.55-7.35 (4H,
m), 6.18 (IH, s), 2.3 (3H, s), 2.18 (3H, s).
(bi) 3-(4-(4-Chlorophenacyl)phenyl)-2,6-dimethy1pyran-4-one, NMR SH (COC13) 7.9-7.75 (4H, m), 7.5-7.35 (4H, m), 6.25 (IH, s), 2.3 (3H, s), 2.2 (3H, s).
(ci) 3-(4-(4-Chlorobenzyl)phenyl)-2,6-dimethylpyran-4-one, NMR SH (COC13) 7.3-6.9 (8H, m), 6.1 (IH, s), 3.9 (2H, s), 2.2 (3H, s),
2.1 (3H, s).
(di) 3-(4-(4-Chlorodifluorobenzyl)phenyl)-2,6-dimethylpyran-4-one, NMR SH (CDC13) 7.95-7.25 (8H, m), 6.25 (IH, s), 2.3 (3H, s), 2.2 (3H, s).
(ei) 3-(3-Chloro-4-(4-chlorophenoxy)phenyl )-2,6-dimethy1pyran-4-one, NMR SH (COC13) 7.4-7.25 (3H, m), 7.1 (IH, dd, J 1, 7Hz), 7.026.9 (3H, s), 6.2 (IH, s) 2.3 (3H, s), 2.2 (3H, s).
(fi) 3-(41-Chloro-4-biphenyly1)-2,6-dimethylpyran-4-one, m.p.
151-153°, NMR SH (CDCl-j).
(gi) 3-(4-Trif1uoromethylphenoxy)-2,6-dimethylpyran-4-one, m.p.
104-105°, NMR £H (CDCl-j) 6.95-7.8 (8H, m), 6.2 (IH, s), 2.3 (3R. s), 2.2 (3H, s).
(hi) 3-(4-(3-Trifluoromethoxyphenoxy)pheny1)-2,6-dimethylpyran-4-one, NMR sH (COC13) 7.3-6.7 (8H,m); 6.2 (lH.s); 2.3 (3H,s); 2.25 (3H,s).
(ii) 2,6-0imethyl-3-(2-pyridyl)pyran-4-one, NMR SH (C0C13) 8.7-8.4 (IH, m), 7.8-6.9 (3H, n»), 6.1 (IH, s), 2.22 (3H, s), 2.18 (3H, s)
J8/LR8/26th February 1991
AP000271
ΡΑΙ137
Preparation 9
3-(4-(4-Trifluoromethy1phenoxy)phenyl )-2.6-dimethylpyran-4-one
A solution of l-(4-(4-trif1uoromethylphenoxy)phenyl)propan-2-one (54.5g) in acetic anhydride (100ml) was added, over 5 min, to a vigorously stirred mixture of polyphosphoric acid (200g) and acetic anhydride (100ml) at 80°. After stirring for 30 min the warm mixture was poured into water (1 litre). The solution was stirred for 30 min then extracted with toluene (3 x 500 ml). The combined extracts were washed with water then satd. aq. sodium bicarbonate, dried over magnesium sulphate and concentrated jn, vacuo to give an oil. Trituration with ether afforded the title compound as a yellow solid (18.20g), m.p. 86-7°, NMR sH (CDCI-j) 6.95-7.8 (8H, m), 6.2 (IH, s),
2.3 (3H, s), 2.2 (3H, s).
Preparation 10
3- (4-(4-trifluoromethoxvphenoxv)phenyl)-2,6-dimethylpvran-4-one
To a vigorously stirred mixture of polyphosphoric acid (60g) and acetic anhydride (26ml) at 90° was added over 15 min a solution of
4- (4-trifluoromethoxyphenoxy) phenylpropan-2-one (9.3g) in acetic anhydride (30ml). The mixture was stirred for a further 30 min at 90° then poured into water (1 litre) and extracted with toluene (2 x 500ml). The combined extracts were washed with water then satd. aq. sodium bicarbonate and dried over magnesium sulphate. Concentration in vacuo gave an orange oil which was chromatographed on silica gel, eluting with dichloromethane then 1:19 methanol/dichloromethane, to give the title compound as an oil (4.lg), NMR iH (CDCl^) 6.9 -7.4 (8H, m), 6.16 (IH, s), 2.24 (3H. s), 2.16 (3H, s).
Preparation 11
2,6-0imethyl-3-(4-(4-methvlsulponylphenoxy)phenvl)pyran-4-one
JB/LRB/26th February 1991
AP Ο 00 2 7 1
PA1137
- 35 To a stirred solution of 2,6-dimethy1-3-(4-(4-methylthiophenoxy)phenyl)pyran-4-one (6.22g) in acetic acid (70 ml) at room temperature was added hydrogen peroxide (15 ml; 30% w/v). After 36 hr the mixture was poured into water and extracted with dichloromethane (2 x 100ml).. The combined extracts were washed with water, satd. aq. sodium bicarbonate and an aq. solution of sodium sulphite, dried over magnesium sulphate and concentrated in vacuo to leave a white solid. Recrystallisation from acetone afforded the title compound (3.39g), m.p. 170-173°, NMR 5H (dg-DMSO) 7.95-7.85 (2H, m), 7.35-7.2 (2H, m),
7.2-7.05 (4H, m), 3.05 (3H, s), 2.3 (3H, s), 2.22 (3H, s).
Preparation 12
3-(2-Pyridy1)propan-2-one
This was prepared from 2-methylpyridine, butyllithium and Ν,Ν-dimethylacetamide according to the procedure of R. Cassity, L.T. Taylor and J. F. Wolfe, J. Org. Chem., 43(11), 2286, (1986).
Example 1
3-(4-(4-Chlorophenoxylphenyl1-2.6-dimethylpyridin-4(lH)-one
3-4-(4-Chlorophenoxy)phenyl)-2,6-dimethylpyran-4-one (lOg) was heated at 150° with 0.880 aq. ammonia (200ml) in a stainless steel autoclave for 18 hr. After cooling the precipitate was filtered off, washed with water, dried in air and recrystallised from DMF to afford the title compound (6.6g), m.p. 271-273°, NMR iH (dg-OMSO) 7.42 (2H, m), 7.18 (2H, π»), 6.95-7.1 (4H, m), 5.95 (1H, s), 2.2 (3H, s), 2.1 (3H, s).
Example 2
3-Bromo-5-(4-(4-chlorophenoxylphenyl1-2,6-dimethylpyridin-4(lH)-one
J8/LRB/26th February 1991
PA1137 c <*A
- 36 To a stirred solution of 3-(4-(4-chlorophenoxy)pheny1)-2,6-dimethylpyridin-4(lH)-one (6.5g) in acetic acid (50ml) was added dropwise, over 30 min, a solution of bromine (1.2ml) in acetic acid (10ml). After 3 hr the mixture was poured into 1% aq. sodium sulphite (250ml). The white precipitate was filtered, washed with water, dried in air and recrystallised from OMF (125ml) to afford the title compound (6.6g), m.p. 306-308°, NMR $H (dg-DMSO) 11.3 (IH, br.s), 7.42 (2H, m), 7.2 (2H, m), 6.95-7.12 (4H, m), 2.42 (3H, s), 2.1 (3H, s).
Example 3
3-Chloro-5-(4-(4-chlorophenoxy)phenvl)-2.6-dimethy1pyridin-4(lH)-one
To a stirred solution of 3-(4-(4-chlorophenoxy)phenyl )-2,6-dimethylpyridin-4(lH)-one (0.8g) in acetic acid (10ml) was added N-chlorosuccinimide (0.39g). The mixture was heated at 100° for 30min, cooled to room temperature and the precipitate filtered and dried in vacuo to afford the title compound (0.33g), m.p. 340-343°, NMR SH (dg-DMSO)
11.3 (IH, br.s), 7.42 (2H, m), 7.2 (2H, m), 6.95-7.12 (4H, m), 2.4 (3H, s), 2.1 (3H, s).
Example 4
3-(4-(4-Trifluoromethvl phenoxy)phenyl )-2,6-dimethy1pyridin-4(lH)-one
3-(4-(4-Trifluoromethy1phenoxy)phenyl)-2,6-dimethylpyran-4-one (2-4g) was heated at 150° with 0.880 aqueous ammonia (30ml) in an autoclave for 18 hours. After cooling the precipitate was filtered off, washed with water, dried in air and recrystallised from DMF to yield the title compound as fine colourless crystals (1.4g). M.p. 258-260°, NMR SH (dg-DMSO) 7.70 (2H, dd, J 5, 0.5Hz), 7.0-7.3 (6H, m), 5.97 (IH,
s), 2.2 (3H, s), 2.1 (3H, s).
Example 5
JB/LR8/26th February 1991
AP Ο Ο Ο 2 7 1
ΡΑ1137
3-8romo-5-(4-(4-trifluoromethylphenoxy)phenvl)-2.6-dimethylpyridin4(lH)-one
To a stirred suspension of 3-(4-(4-trifluoromethylphenoxy)phenyl)2,6-dimethyl pyridin-4(lH)-one (4.12g) in chloroform (50ml) at room temperature was added N-bromosuccinimide (2.25g). After 2hr the mixture was filtered and the solid washed with chlorofrom and dried jn vacuo. Recrystallisation from DMF afforded the title compound (2.18g), m.p. 304-305°, NMR 5H (dg-DMSO) 7.70 (2H, dd, J 5, 0.5Hz), 7.0-7.3 (6H, m), 2.42 (3H, s), 2.1 (3H, s).
Example 6
3- (4'-Chloro-4-biphenylyl)-2,6-dimethylpyridin-4(lH)-one
This was prepared from 3-(4'-chloro-4-biphenylyl)-2,6-dimethylpyran4- one in a similar manner to example 1. M.p. >350° (decomp.), NMR 5H (dg-DMSO) 7.55-7.75 (4H, m), 7.45-7.55 (2H, m), 7.2-7.3(2H, m), 5.95 (IH, s), 2.2 (3H, s), 2.1 (3H, s).
Example 7
3-Bromo-5-(41-chloro-4-bipheny1yl)-2,6-dimethylpyridin-4(lH)-one
This was prepared from 3-(4'-chloro-4-biphenylyl)-2,6-dimethylpyridin4(lH)-one in a similar manner to example 2. M.p. 300° (decomp.), NMR iH (dg-DMSO) 7.6-7.8 (4H, m), 7.45-7.55 (2H, m). 7.22-7.35 (2H, m),
2.4 (3H, s), 2.15 (3H, s).
Example 8
3-Chloro-5-(4,-chloro-4-biphenylyl)-2.6-dimethvlpyridin-4(lH)-one
This was prepared from 3-(41-chloro-4-biphenylyl)-2,6-dimethylpyridinJB/LRB/26th February 1991
- 38 PA1137 ο «ΙΑ
4(lH)-orte in a similar manner to example 3. M.p. >350° (decomp.), NMR SH (dg-DMSO) 7.6-7.8 (4H, m), 7.45-7.55 (2H, m), 7.22-7.35 (2H, m), 2.4 (3H, s), 2.15 (3H, s).
Example 9
5-Iodo-2.6-dimethyl-3-octvlpyridin-4(lH)-one
To a stirred solution of 2,6-dimethyl-3-octylpyridin-4(lH)-one (1.17g) and iodine (0.63g) in ethanol (15ml) at 70° was added dropwise a solution of iodic acid (0.22g) in water (1ml). After 30 min the mixture was allowed to cool and a few drops of an aqueous sodium sulphite solution added to remove excess iodine. The precipitate was filtered, washed with ethanol and recrystallised from OMF to give the title compound (0.93g), m.p. 224-226°, NMR SH (dg-DMSO) 2.42 (3H, s),
2.3-2.5 (2H, m), 2.2 (3H, s), 1.1-1.45 (12H, m), 0.85 (3H, t).
Example 10
5-Cyano-2.6-d imethy 1-3-octyl pyr id in-4(lH)-one
A mixture of 5-iodo-2,6-dimethyl-3-octylpyridin-4(lH)-one (0.54g) and cuprous cyanide (0.4g) in pentan-l-ol was stirred and refluxed for 12hr. After cooling the solvent was evaporated jn vacuo and the residue chromatographed on silica gel, eluting with 1:19 methanol/ dichloromethane to afford the title compound (O.llg), m.p. 205-206°, NMR $H (dg-DMSO) 11.7 (IH, br.s), 2.38 (3H, s), 2.2-2.5 (2H, m), 2.25 (3H, s), 1.1-1.45 (12H, m), 0.85 (3H, t).
Example 11
3-(4-Chlorophenyl )-1.2.6-trimethylpyridin-4-one
3-(4-Chlorophenyl)-2,6-dimethylpyran-4-one (2.27g) was heated at 150° with a solution of methylamine in ethanol (35ml; 33% w/w) in an autoJB/LRB/26th February 1991
PA1137
AP Ο Ο ο 2 7 1
- 39 clave for 12 hr. The mixture was concentrated in vacuo, triturated with ether and filtered, to afford the title compound (1.2g), m.p. 221-222°, NMR 5H (dg-DMSO) 7.42 (2H, d, J 5Hz), 7.1 (2H, d, J 5Hz),
6.1 (1H, s), 3.5 (3H, s), 2.32 (3H, s), 2.15 (3H, s).
Example 12 ·<
3-Bromo-5-(4-Chloropheny1)-1.2.6-trimethy1pyridin-4-one
To a stirred solution of 3-(4-ch1oropheny1)-1,2,6-trimethylpyridin-4one (0.5g) in acetic acid (5ml) was added dropwise a solution of bromine (0.1ml) in acetic acid (1ml). After 5 min the mixture was poured into water. The solid was filtered off, washed with water and recrytal1ised from ethanol (10ml) to give the desired compound (0.25g), m.p. 264-266°, NMR SH (COClj) 7.3-7.4 (2H, m), 7.05-7.2 (2H, m), 6.95-7.12 (4H, m), 3.65 (3H, s), 2.7 (3H, s), 2.2 (3H, s).
Example 13
3-(4-(4-Trifluoromethoxyphenoxy)pheny1)-2,6-dimethylpyridin-4(lH)-one
3-(4-(4-Trifluoromethoxyphenoxy)phenyl)-2,6-dimethylpyran-4-one (4.1g) was dissolved in ethanol (10ml) and heated in a stainless steel autoclave with 0.880 ammonia (35ml) at 150° for 24 hr. After cooling the crystalline precipitate was filtered off, washed with eth/T acetate and dried jn vacuo to afford the title compound (2.78g), m.p. 244-248°, NMR 6H (dg-DMSO) 11.1 (1H, br. s) 7.4 (2H, m), 7.1-7/3 (4H, m), 7.02 (2H, m), 5.95 (1H, s), 2.2 (3H, s), 2.08 (3H, s).
Example 14
3-Bromo-5-(4-(4-trifluoromethoxvphenoxv)phenvl)-2.6-dimethylpyrid in-4 (lH)-one
This was prepared in a similar manner to example 5 from 3-(4-(4-triJB/LRB/26th February 1991
PA1137 , \ SI) ΰ ο RA
- 40 f luoromethoxyphenoxy)phenyl)-2,6-dimethylpyridin-4(lH)-one, m.p. 284-286°, NMR SH (dg-DMSO) 7.3-7.45 (2H, m), 7.1-7.3 (4H, m), 7-7.1 (2H, m), 2.45 (3H, s), 2.12 (3H, s).
Example 15
3-Chloro-5-(4-(4-trifluoromethoxyphenoxy)phenyl )-2,6-dimethylpyridin4( lH)-one
A mixture of 3-(4-(4-trifluoromethoxyphenoxy)phenyl)-2,6-dimethylpyridin-4(lH)-one (0.37g) and N-chlorosuccinimide (0.16g) in chloroform was stirred at room temperature for 3 days. The precipitate was filtered off and recrystal 1ised from OMF to afford the title compound (O.lg), m.p. 298-302°, NMR SH (dg-DMSO) 7.35-7.5 (2H, m), 7.1-7.3 (4H, m), 7-7.1 (2H, m), 2.38 (3H, s), 2.1 (3H, s).
Example 16
3- Bromo-2,6-dimethyl-5-(4-(4-methylsulphinylphenoxy)pheny1)pyridine4- one
To a stirred solution of 2,6-dimethyl-3-(4-(4-methylthiophenoxy)phenyl)pyridine-4-one (lg) in acetic acid (10 ml) was added dropwise a solution of bromine (0.34 ml) in acetic acid (5 ml). After 1 hr a few drops of an aq. sodium sulphite solution was added to discharge excess bromine. The mixture was then poured into water, the precipitate filtered, dried and recrystallised from OMF to afford the title compound (0.57g), m.p. 262-263°, NMR iH (dg-DMSO) 7.8-7.65 (2H, m),
7.3-7.15 (4H, m), 7.15-7.05 (2H, m), 2.75 (3H, s), 2.4 (3H. s), 2.1 (3H, s).
3 4
The following compounds wherein R is hydrogen, R and R are both c methyl and R is hydrogen were prepared in an analogous manner to Example 1, the remaining compounds by a method analogous to Examples 2 and 3.
JB/LRB/26th February 1991
PA1137
Example
No.
AP000271
R1 R2 M.p./°C
Br _/ 280-5
Cl ' =/ 338-40
21
H
Br
Cl
316-9
320-1 >330 (dec)
Br A. F 276'8
Cl \=z/ 361-4
Br
315-317
29
Η _Α' 310-13
Br _/Avci 301-3
Cl 325-8
Cl
246-8
320-1
Br
H
OMe
296-8
246-8
JB/LRB/26th February 1991 bad original
PA1137
Example
No.
H
Br r n’oοosa
R2
>340 (dec.) 308-11
Br >340 (dec.) >330 (dec.) >330 (dec.)
293-6
291-3
319-21
275-77
261-3
299-300
265-8
272-6
292-4
>325 (dec.) >330 (dec.) >345 (dec.)
247-50
260-3
JB/LRB/26th February 1991
PA1137
Example
No.
AP Ο 00 2 7 1
H 7—\ /7—7 268-70 (dec.)
Br ~V ; ~0 C 256-60
Cl
Br
Cl ' 1
>300 (dec.) >320 (dec.)
Br
H
326-7
H 130-2 Br CQH17 250-5 Cl 222-4
H
Br
314-6
278-81
H
Br ch2
249-50
310-12
H
Br
342-4
289-90
JB/LRB/26th February 1991
BAD ORIGINAL $
PA1137
H
Br
Cl
H
Br
Br
H
Br
H
Br
Cl
H
Br
Cl
H
Br
Cl
// W
// 'λ
SMe
334-9
323-6
358-60
278-280
300-303
253-255
262-263
303-305
308-310
232-234
286-290
268-272
288-291 (dec.)
313-315
333-335
299-301 (dec.) 305-308 340-344 (dec.)
BAD ORIGINAL
February 1991
AP000271
- 45 - PA1137
Example No. R1 R2 M.p./°C
82 H --V _ct 294-298
83 Br 323-324 (dec.)
84 Cl Cl 317-319 (dec.)
Br
314-315
Br
H
'/ Wc
287-289
252-253
Example 88
3-(4-(3-Trifluoromethoxyphenoxy)phenyl )-2,6-dimethylpyridin-4(lH)-one
This was prepared from 3-(4-(3-Trif1uoromethoxyphenoxy)pheny1)-2,6dimethyl pyran-4-one in a similar manner to example 13. m.p. 244-246o, Nmr 5H (d6-DMS0) 11.1 (IH, br. s) 7.5 (2H, m), 7.25-7.0 (7H, m),
5.95 (IH, s), 2.2 (3H, s), 2.08 (3H, s).
Example 89
3-Bromo-5-(4-(3-trif1uoromethoxyphenoxy)phenyl)-2,6-dimethylpyridin-4(lH)-one
This was prepared in a similar manner to example 5 from 3-(4-(3-trif luoromethoxyphenoxyJphenyl)-2,6-dimethylpyridin-4(lH)-one
m.p. 274-277°, Nmr 5H (d6-DMS0) 7.6-7.45 (IH, m), 7.3-7.0 (7H. m), 2.45 (3H, s), 2.1 (3H, s).
JB/LRB/26th February 1991 'BAD ORIGINAL
PA1137
Example 90
3-Chioro-5-(4-(3-trifluoromethoxyphenoxy)phenyl)-2,6-dimethyIpyridin-4(lH)-one
A mixture of 3-(4-(3-trif1uoromethoxyphenoxy)phenyl)-2,6dimethylpyridin-4(lH)-one (lg) and N-chlorosuccinimide (0.43g) in chloroform (30ml) was stirred and refluxed for 5 hours. After cooling to room temperature the precipitate was filtered off and recrystallised from DMF to afford the title compound (0.23g), m.p. 249-253°, Nmr 5H (d6-DMS0) 11.6 (1H, br s), 7.6-7.5 (1H, m), 7.3-7.05 (7H, m), 2.4 (3H, s), 2.1 (3H, s).
Example 91
3- Bromo-2,6-dimethyl-4-methoxy-5-f4-(4-trif luoromethoxyphenoxy) phenylIpyridine
A mixture of 3-Bromo-5-(4-(3-trifluoromethoxyphenoxy)phenyl)-2,6dimethyl pyridin-4(lH)-one (1.5g), potassium carbonate (0. 33g) and methyl iodide (2ml) in dry DMF (25ml) was stirred at room temperature for 24 hours. The mixture was diluted with water and extracted with chloroform, washed with water, dried over magnesium sulphate and evaporated in vacuo. The residue was chromatographed on silica, eluting with 99:1 dich1oromethane:methanol, to give the title compound (0.4g), m.p. 39-41°, Nmr sH (CDC13) 7.3-7.0 (8H, m), 3.7 (3H, s), 2.7 (3H, s), 2.3 (3H, s).
Example 92
4- Acetoxy-3-chloro-2.6-dimethy1-5-(4-(4-trifluoromethoxyphenoxy) phenylIpyridine
To a stirred suspension of 3-Chloro-5-(4-(4-trifluoromethoxyphenoxy)
JB/LRB/26th February 1991
PA1137
AP ο 00 2 7 4
- 47 phenyl )-2,6-dimethyl pyridin-4(1H)-one (0.41g) in dry DMF, under nitrogen, was added all at once sodium hydride (0.05g of a 60% dispersion in mineral oil). After stirring at rt for 30 min acetyl chloride (0.14ml) was added. The mixture was stirred at rt for a further 2 hr, poured into iced water, extracted with ether, washed with water and satd. aq. sodium bicarbonate and dried over magnesium sulphate. Evaporation gave an oil which was triturated with hexane to give the title compound (0.2g), m.p. 78-80°, Nmr 4H (CDC13) 7.3-7.0 (8H, m), 2.68 (3H, s), 2.35 (3H, s), 2.05 (3H, s).
Example 93
3-(4-(4-Chlorophenoxylphenyl)-l-hvdroxy-2.6-dimethylpyridin-4-one
A mixture of 3-(4-(4-chlorophenoxy)phenyl)-2,6-dimethylpyran-4-one (l.Og), hydroxylamine hydrochloride (1.06g) , sodium acetate (1.25g) and water (5ml) in ethanol (10ml) was heated at reflux for 3 days. After cooling to rt the mixture was diluted with water (20ml) and the precipitate filtered off and washed with ethyl acetate. Recrystallisation from DMF afforded the title compound (0.2g), m.p. 232-2360, NMR dH (d6-DMS0) 7.5-7.4 (2H, d, J 8Hz), 7.3-7.2 (2H, d, J 8Hz), 7.15-7.0 (4H, m), 6.75 (1H, s), 2.35 (3H, s), 2.15 (3H, s).
Example 94
3-8romo-5-(4-(4-chlorophenoxy)phenyl)-l-hydroxy-2.6-dimethylpyridin-4-one
To a stirred solution of 3-(4-(4-chlorophenoxy)phenyl)-l-hydroxy-2,6dimethyl pyridin-4-one (0.5g) in acetic acid (10ml) was added dropwise a solution of bromine (0.08ml) in acetic acid (1ml). After 1.5 hour a few drops of an aq. sodium sulphite solution was added to discharge excess bromine. The mixture was diluted with water and the precipitate filtered,washed with water, dried and recrystallised from OMF to afford the title compound (0.32g), m.p. 246-2500 (dec.), NMR dH
JB/LRB/26th February 1991
PA1137 f · $ ο ο 0 AA
- 48 (d6-0MS0) 7.5-7.4 (2H,d, J 8Hz), 7.25-7.15 (2H.d, J 8Hz), 7.15-7.0 (4H,m), 2.6 (3H,s), 2.1 (3H,s).
Example 95
3-Bromo-2,6-dimethy1-5-Γ4-(4-trifluoromethoxyphenoxv)phenylΊ-4-pyridinyl diethyl phosphate
To a solution of 3-8romo-5-(4-(4-trifluoromethoxyphenoxy)phenyl)
-2,6-dimethy1 pyridin-4(lH)-one (4.44g) in dry DMF (30ml) under nitrogen was added sodium hydride (0.39g of a 60V dispersion in mineral oil). After stirring at rt for 30 min diethyl chlorophosphate (2.1ml) was added dropwise. The mixture was stirred at rt for 48 hr then filtered. The filtrate was diluted with toluene (200ml), washed with 2M sodium carbonate, dried over magnesium sulphate and concentrated in vacuo. The residue was chromatographed on silica, eluting with 1:4 ethyl acetate:dichloromethane to afford the title compound (1.22g), m.p. 80-81o, NMR dH (CDC13) 7.35-7.0 (8H, m), 4-3.8 (4H, m,), 2.7 (3H, s), 2.25 (3H, s), 1.25-1.15 (6H, 2 x t). Parmaceutical Formulations
The following examples illustrate, pharmaceutical formulations which may be employed in accordance with the present invention:A. Injectable solution
A solution for intramuscular injection may be prepared by mixing:-
Compound of formula (I) 9.5 parts by weight
Dimethyl sulphoxide 19.0 parts by weight
Sorbitan monooleate 4.5 parts by weight
Corn oil 67.0 parts by weight
100.0
J8/LR8/26th February 1991
ΡΑ1137
AP Ο Ο Ο 2 7 1
- 49 8.
C.
D.
Injectable solution
Compound of formula (I) 5 parts by weight
N-methy1-pyro11i done 48.3 parts by weight
Tween 80 2 parts by weight
Span 80 4.7 parts by weight
Miglyol 812 40 parts by weight
100.0
Tablet
Compound of formula (I) 25.0 mg
Lactose BP 48.5 mg
Microcrystalline Cellulose BP 10.0 mg
(Avicel pH 101)
Low-substituted Hydroxypropyl; 10.0 mg
Cellulose BP (LHPC LH-ll*')
Sodium Starch Giycollate BP 3.0 mg
(“Explotab)
Povidone BP (K30) 3.0 mg
Magnesium Stearate BP 0.5 mg
100.0 mg
Oral suspension
Compound of formula (I) 50 mg
Avicel RC 591 75 mg
Sucrose syrup 3. .5 ml
JB/LRB/26th February 1991
PA1137
Methyl hydroxybenzoate 5 mg
Colour 0.01% w/v
Cherry flavour 0.1 % v/v
Tween 80 0.2 % v/v
Water to 5 ml
E. Injectable suspension
Compound of formula (I) 100 mg
Polyvinyl pyrrolidone (PVP) 170 mg
Tween 80 0.2% v/v
Methylhydroxybenzoate 0.1% w/v
Water for Injection to 3 ml
F. Capsule
Compound of formula (I) 100 mg
Starch 1500 150 mg
Magnesium stearate 2.5 mg filled into a hard gelatin capsule
Biological test results
1. In vitro activity vs. Plasmodium falciparum
The in vitro activity of the test compounds was determined using a modification of the semi-automated microdilution technique of Oesjardins et aj. (1979). Initial dilutions were prepared from l/100th molecular weight (in mg) of the compounds dissolved in dry ethanol, with the first 1:100 dilution being in ethanol and subsequent dilutions in RPMI 1640 medium supplemented with 10% v/v human plasma. Serial 1:2 drug dilutions were prepared in microtitration trays using microdiluters, each dilution being set up in triplicate. To this was added RPMI 1640 medium suppleJB/LR8/26th February 1991
ΡΑ1137
AP Ο Ο Ο 2 7 1
- 51 merited with 10% v/v human plasma, fresh and infected type A Rhesus positive human erythrocytes to yield a haematocrit of 3% and a parasitaemia of 0.25-0.5%. [^H]-hypoxanthine was added to give a final concentration of 12.5-16pCi/ml of culture. The plates were sealed and incubated in a modular incubator in a gas mixture of 5% 02; 3% C02 and 92% N2 by volume at 37°C. The test was completed as described by Desjardins et at (1979). Data were analysed to yield ICjjq values by best fit to a sigmoidal dose-response curve. The results are given in Table 1 below.
JB/LRB/26th February 1991
- 52 PA1137
TABLE 1
In vitro activity vs Plasmodium fa Iciparum
Compound of IC50 No. of
Example No: tests
1 2.5 (4)
2 0.2 (17)
3 1.4 (2)
4 1.1 (1)
5 0.22 (9)
6 8.4 (4)
7 2.0 , (2)
8 0.5 (9)
10 2.3 (1)
12 23.5 (1)
14 0.023 (6)
15 0.02 (5)
16 1.6 (1)
2. I η v i vo activity vs. P.yoelii in the mouse
In vivo activity was determined using the modified 4-day suppressive test involving an infection of the YM strain of P.yoe1ii by 3x10® parasitized erythrocytes/ml and 7 oral doses given in 4 days in CD1 mice. Drugs were formulated by ball milling overnight in 0.25% celacol with stainless steel balls to form a fine particle suspension. The total requirement was formulated at the beginning of a test and thereafter stored at 4°C. On the morning of day 5 smears of tail blood were prepared from each mouse, the parasitaemias counted and the inhibition as compared to control animals calculated. Data were analysed to
JB/LRB/26th February 1991
ΡΑ1137
AP Ο Ο Ο 2 7 1
- 53 yield EO^q values by the best fit to a sigmoidal dose response curve, and the results are presented in Table 2 below.
TABLE 2
Mouse 4-day suppressive test vs P.voelii
Compound of ED50 No. of
Example No: (jpg/M tests
1 2.5 (1)
2 0.7 (2)
3 1.6 (1)
4 1.25 (1)
5 0.26 (2)
6 1.6 (1)
7 1.4 (1)
a 0.6 (4)
12 16.4 (1)
14 0.34 (1)
15 0.19 (1)
JB/LRB/26th February 1991
PA1137PCT

Claims (19)

Claims
1 together with a pharmaceutically or veterinarily acceptable ) carrier therefor.
1 3 4 2 (viii) when R is hydrogen and R and R are both methyl, R is not a 5-phenyl-1,3,4-oxadiazole-2-yl group, an isoquinolyl group or an unsubscituted phenyl group;
or a salt or ocher physiologically functional derivative thereof.
A compound according of formula (IB):
to claim 1 (IB)
1 ‘34 5 (vii) when R is hydrogen, R and R are both methyl and R is hydrogen, R is not propyl;
1 3 4 5 (iv) when R is hydrogen, R and R are both hydrogen, R is methyl and R is a phenyl group substituted in the 3 posicion relative co the pyridone ring by a group
X is not -0-, S(0) , -OCH-- or a single bond linking the m ί phenyl groups;
1. A compound of formula (I):
wherein represents a hydrogen or halogen atom, or a cyano group;
R represents a carbocyclic group having 6 to 10 ring atoms and containing at least one aromatic ring; or a heterocyclic group having 5 to 10 ring atoms, including 1 to 4 heteroatoms selected from
0,N and S, and containing at least one aromatic ring, said carbocyclic and heterocyclic groups being optionally substituted by a substituent selected from halogen, cyano, nitro, amino, mono- or di-C^ ^alkylamino, ^alkyl, haloC^ ^alkyl, ^alkoxy, C^ ^alkylsulphonyl, ^alkylthio,
C^^alkanoyl, pyridyl optionally substituted by haloC^ ^alkyl, pyridyloxy optionally substituted by haloC. alkyl or the 2 carbocyclic or heterocyclic group R is optionally substituted by a group
- ( X )
CMR/JJ/14th April, 1992.
PA1137PCT
AP Ο Ο Ο 2 7 1
2.
i r
ι ι
AP ο ο η 2 7 1
- 2 wherein
X represents -Ο-, -C-, S(O)m, -CHjO-, -OCHj-, -CH2S(O)m,
-S(O)bCH2-, -CYZ(CH2)p or -(CHppCYZ, or X Is a single bond linking the phenyl groups;
Y and Z Independently represent hydrogen, halogen or ^alkyl;
R$ represents halogen, cyano, nitro, amino, mono- or dl-(C^_^) alkylaalno, ^alkyl, halo(C^ ^)alkyl, ^alkoxy or halo(C^ ^)alkoxy, or S(O)bC^ alkyl;
n Is zero or an integer from 1 to 5;
m is zero, one or two; and p is zero or one;
the carbocycllc or heterocyclic group R being optionally further substituted by one or two substituents selected from halogen, cyano, nitro, amino, mono- or dl-(C^ ^)alkylamlno, ^alkyl, halo(C^ ^)alkyl, ^alkoxy and ^alkylthio;
or R represents a ^cycloalkyl group or a C^^cycloalkyl- ^alkyl group, wherein the cycloalkyl group or moiety Is optionally substituted by ^alkyl, ^cycloalkyl or by a phenyl group which may Itself be optionally substituted by (R^)n as defined above;
or R represents * ^^alkyl group, optionally substituted by hydroxy or Cigalkoxy, or by a carbocycllc or heterocyclic group as defined above;
CMR/JJ/14th April, 1992.
PA1137PCT ·' ·' ·’ ο μα
R·' and R”, which may be che same or different, each represent a hydrogen or halogen atom, or a ^alkyl group optionally substituted by 1 to 3 halogen atoms; and „5
R represents a hydrogen atom, a hydroxyl group, or a ^alkyl group, optionally substituted by hydroxy, carboxy, amino or mono- or di- (C^ ^)alkyl amino, provided that :13 4 5 (1) when R is cyano, R and R are both hydrogen and R is 2 methyl, ethyl, acetoxy or hydroxy, R la not a phenyl group or a phenyl group substituted by a substituent selected from halogen, nitro, ^alkyl, C^_2alkoxy, or _ 2aikyisulph°nyi;
3- bromo- 2,6 -d ime thy1- 5- (4- (3-1 r i fluorome thoxyphenoxy)phenyl] pyridln-4(lH)-one
3-chloro-2,6-dimethyl-5-(4- (3-trifluoromethoxyphenoxy)phenyl] pyrldln-4(lH)-one
3-chloro-2,6-dimethyl-5-[4-(3-trlfluoromethylphenoxy)phenyl] pyrIdIn-4(IH)-one
3-Bromo-2,6-dimethyl-5-[4-(3-trlfluoromethylphenoxy)phenyl] pyridln-4(ltJ)-one
3-chloro-5- (4- (4-trifluoromethoxyphenoxy)phenyl)-2,6-dlmethylpyrldln-4(lH)-one
3-Bromo-5 - (4- (4- tr if luoromethoxyphenoxy) phenyl) -2,6-dime thy 1pyridin-4(lH)-one
3-Bromo-5-(4-(4-trifluoromethylphenoxy)phenyl]-2,6-dlmethylpyridin-4(ljj) -one
, 3-Bromo-5-(4-(4-chlorophenoxy)phenyl]-2,6-dimethylpyridin-4(lH)one
3 4
3. A compound according to claim 1 or claim 2 wherein R^ Is a hydrogen atom or a halogen atom.
4- acetoxy-3-chloro-2,6-dimethyl-5- (4- (4-trlfluorome thoxyphenoxy) phenyl]pyridine.
4. ( A compound according to any of claims 1 to 3 wherein R Is a
Cj^cycloalkyl group, optionally substituted by a ^alkyl group or by a phenyl group, which Itself may be optionally substituted 2 by a halogen; or R is an aromatic carbocyclic group optionally substituted by one or two halogen atoms, or by a ^alkoxy, halo ^alkyl, phenyl, phenoxy, phenylsulphonyl, phenylthlo, benzyl, α,α-difluorobenzyl, benzoyl or pyridyloxy group, wherein a phenyl or pyridyl group or moiety in the aformentloned substituents may itself be optionally substituted by one or two substituents selected from halo; haloC^ ^alkyl; ^alkoxy; haloC^ ^alkoxy; or S(0)mC^ ^alkyl wherein a is zero, one or two.
5. A compound according to any of claims 1 to 3 wherein R is an aromatic carbocyclic group optionally substituted by phenyl, pyridyl, halogen, cyano, nitro, amino, mono- or di-(C^ )alkyl-amino, ^alkyl, halo-(C^_^)alkyl, C^^alkoxy, phenoxy, ^alkylsulphonyl, ^alkylthio, ^alkanoyl, phenylsulphonyl, phenylthlo or benzoyl, wherein a phenyl group or moiety or a pyridyl group in the aforementioned substitutents may itself be further optionally substituted by halogen, cyano, nitro, amino, mono- or di(C^ ^)alkylamino, C^^alkyl, halo-(C14)alkyl, 4alkoxy, halo(C14)alkoxy, or
-S(O)aC^ ^alkyl, where m is zero, 1 or 2.
5 2 1 4 and R is hydrogen, R is not ^alkyl;
- 6 - PA1137PCT
6. A compound according to any of claims 1 to 5 wherein R and R each represent a Chalky! group.
CMR/JJ/14th April, 1992.
AP0 00 2 7 1
7. A compound according co any of claims 1 co 6 wherein la a hydrogen acorn.
8. A compound according to claim 1 of formula (IC) vherein rI represents halogen;
R3 and r\ which may be che same or dlfferenC each represenC a Cl-4alkyl 8rouP·
R^ represents a hydrogen acorn;
X represencs -0-, -<L, S(0)a, -CH^O-, -OCHj-, -CH2S(0)m,
-S(0)mCH2·, -CYZ(CH2)p or -(CHppCYZ, or X is a single bond linking the phenyl groups;
Y and Z independently represent hydrogen, halogen or alkyl;
r6 represents halogen, cyano, nitro, amino, mono- or dl-(C^ alkylamlno, 4 alkyl, halo(C14)alkyl, CV4 alkoxy, halo(C^ alkoxy; or -S(0)a alkyl;
n Is zero or an integer from 1 to 5 a is zero, one or two; and
BAD ORIGINAL
CMR/JJ/l4th April, 1992.
PA1137PCT p Is zero or one;
or a physiologically acceptable salt or other physiologically functional derivative thereof.
9. A compound according to claim 1 selected from:
9 10 represents a C. alkyl group; or a group -0P(0)(0R ) (OR ), 9 1 10 wherein R and R , which may be the same or different, each represent hydrogen or a alkyl group.
10. A therapeutic formulation comprising a compound of formula (I) (I)
CMR/JJ/l4th April, 1992.
PA1137PCT
AP Ο Ο Ο 2 7 1 wherein
R? represents a hydrogen or halogen atom, or a cyano group;
R represents a carbocycllc group having 6 to 10 ring atoms and containing at least one aromatic ring; or a heterocyclic group having 5 to 10 ring atoms, Including 1 to 4 heteroatoms selected from
0,N and S, and containing at least one aromatic ring, said carbocycllc and heterocyclic groups being optionally substituted by a substituent selected from halogen, cyano, nitro, amino, mono-or di-C^ ^alkylamino, C^alkyl, •haloC^ ^alkyl, ^alkoxy, ^alkylsulphonyl, ^alkylthio,
C^^alkanoyl, pyridyl optionally substituted by haloC^ ^alkyl, pyridyloxy optionally substituted by haloC. .alkyl or the 2 carbocycllc or heterocyclic group R Is optionally substituted by a group
-(X) ( R6)n wherein
X represents -0-, S(0)m, -CHjO-, -OCHj-, -0^8(0)11,
-S(0)mCH2-, -CYZ(CH2)p or -(CHppCYZ, or X is a single bond linking the phenyl groups;
Y and Z independently represent hydrogen, halogen or C^alkyl;
CMR/JJ/14th April, 1992.
PA1137PCT
R represents halogen, cyano, nitro, amino, nono- or di<Cl-4) alkylamino, C^alkyl, halo(C^ ^)alkyl, ^alkoxy or halo(C^ 4)alkoxy, or s<0)ec1.4 «Ikyl;
n is zero or an integer from 1 to 5;
a is zero, one or two; and p is zero or one;
the carbocyclic or heterocyclic group R being optionally further substituted by one or tvo substituents selected iron halogen, cyano, nitro, amino, mono- or di-)alkylamino, ^alkyl, halo(C| ^)alkyl, ^alkoxy and ^alkylthio;
or R represents a Cj gcycloalkyl group’or a ^cycloalkyl- ^alkyl group, wherein the cycloalkyl group or moiety is optionally substituted by C. .alkyl, C, .cycloalkyl or by a phenyl group X o j · v which may itself be optionally substituted by (R )n as defined above;
or R represents a 1Qalkyl group, optionally substituted by hydroxy or
C, .alkoxy, or by a carbocyclic or heterocyclic group as 1 · o defined above;
R3 and R4, which may be the same or different, each represent a hydrogen or halogen atom, or a fialkyl group optionally substituted by 1 to 3 halogen atoms; and r5 represents a hydrogen atom, a hydroxyl group, or a ^alkyl group, optionally substituted by hydroxy, carboxy, amino or mono- or di- (C^ ^)alkyl amino,
CMR/JJ/T4th April, 1992.
PA1137PCT
APO0027j or « salt or other physiologically functional derivative thereof, l
11. A therapeutic formulation according to claim 10 vhlch includes a : further therapeutic agent.
I .
12. A therapeutic formulation according to claim 11 wherein the further therapeutic agent ls a hydroxynaphthoquinone.
12 3 4 wherein R , R , R and R are as hereinbefore defined and R 8 represencs a ^alkyl group; a group OC(O)R wherein R
CMR/JJ/14th April, 1992.
PA1137PCT
13. A therapeutic formulation according to any of claims 10 to 12 in i
unit dose form.
13 4 5 (vi) when R is hydrogen, R is methyl, R is C. .alkyl and R is hydrogen or methyl, R is not methyl;
13 4 (v) when R is hydrogen, R is C. .alkyl, R is butyl or pentyl
13 4 5 (iii)when R is hydrogen, R and R are both hydrogen and R is methyl, R is not a phenyl group substituted in the 3 position relative to the pyridone ring by a substituent selected from halogen, nitro, C^ ^alkyl, haloC^_^alkyl, C| ^alkoxy, C^ ^alkylthio or C^ ^alkylsulphonyl;
CMR/JJ/14th April. 1992.
PA1137PCT
I )
I f
[
I
F j
13 4 5 (ii) when R is cyano R and R are both hydrogen, R is methyl, ethyl, acetoxy or hydroxy and R is a phenyl group substituted by a group
X is not -OCH»-, -S(0) CH,-, -CYZ(CH)- or -(CH,) CYZ-,
Z m z z p c. p where Y and Z are both hydrogen or one of Y and Z is methyl and the other is hydrogen.
; 14. A method for the preparation of a therapeutic formulation : according to any of claims 10 to 13 comprising bringing into • association a compound according to any of claims 1 to 9 and a
J pharmaceutically or veterinarily acceptable carrier therefor, and j optionally a further therapeutic agent.
i
I ί
15. A method for the treatment and/or prophylaxis of parasitic j Infections vhlch comprises administering to a mammal suffering , from a susceptible to said infection an effective amount of a compound of formula (I) as defined in claim 10.
•
J ί
16. A compound of formula (I) as defined in claim 10 for use in ί therapy.
I j
17. The use of a compound of formula (I) as defined in claim 10 for the manufacture of a medicament for the treatment and/or prophylaxis of parasitic infections.
i
! 18. A process for the preparation of a compound according to any of
I claims 1 to 9 which comprises
CMR/JJ/14th April, 1992.
PA1137PCT j ν ί ii iiMA (A) to prepare a compound of formula (I) wherein R^ represents a hydrogen atom the reaction of a compound of formula (II) (II) with ammonia or a derivative thereof;
(B) to prepare a compound of formula (I) wherein R3 Is a halogen atom, the reaction of a compound of formula (I) wherein R^ is hydrogen with a halogenating agent;
(C) to prepare a compound of formula (I) wherein R^ is a cyano group, the reaction of a compound of formula (I) wherein R3
Is iodine, with a metal nitrile;
(D) to prepare a compound of formula (IB), the reaction of a compound of formula (I) with an alkylating, acylating or phosphorylating agent;
followed where necessary or desired by salt formation.
19. A novel intermediate of formula (II) □
wherein R
R3 and R4 are as defined in claim 1.
(II)
APAP/P/1991/000243A 1990-03-12 1991-03-12 New pyridones and the use of pyridones in chemotherapy. AP271A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909005518A GB9005518D0 (en) 1990-03-12 1990-03-12 Heterocyclic compounds

Publications (2)

Publication Number Publication Date
AP9100243A0 AP9100243A0 (en) 1991-04-30
AP271A true AP271A (en) 1993-06-24

Family

ID=10672464

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1991/000243A AP271A (en) 1990-03-12 1991-03-12 New pyridones and the use of pyridones in chemotherapy.

Country Status (17)

Country Link
EP (1) EP0447164A1 (en)
JP (1) JPH05504961A (en)
AP (1) AP271A (en)
CA (1) CA2078147A1 (en)
CS (1) CS63591A2 (en)
FI (1) FI924071A (en)
GB (1) GB9005518D0 (en)
HU (1) HUT68035A (en)
IE (1) IE910790A1 (en)
IL (1) IL97501A (en)
MY (1) MY106873A (en)
NZ (1) NZ237377A (en)
OA (1) OA09684A (en)
PT (1) PT97002A (en)
TW (1) TW201734B (en)
WO (1) WO1991013873A1 (en)
ZA (1) ZA911791B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2244054B (en) * 1990-04-19 1994-04-06 Ici Plc Pyridine derivatives
FR2687674B1 (en) * 1992-02-07 1995-05-19 Roussel Uclaf NEW PYRIDONE DERIVATIVES, THEIR PREPARATION PROCESS, THE NEW INTERMEDIATES OBTAINED, THEIR APPLICATION AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
WO1997028127A1 (en) * 1996-02-02 1997-08-07 Kumiai Chemical Industry Co., Ltd. Pyridone derivatives and herbicides
EP1858876A2 (en) * 2005-03-04 2007-11-28 Glaxo Group Limited Pyridinone derivatives against malaria
AR060974A1 (en) * 2006-05-31 2008-07-23 Glaxo Group Ltd COMPOSITE OF 4-PIRIDINONE, ITS USE FOR THE PREPARATION OF A MEDICINAL PRODUCT, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, PROCESS FOR ITS PREPARATION AND PROCESS FOR THE PREPARATION OF AN INTERMEDIATE UTILITY COMPOUND ABOVE
EP1967515A1 (en) * 2007-03-08 2008-09-10 Glaxo Group Limited Heterocyclic compounds
EP1862459A1 (en) * 2006-05-31 2007-12-05 Glaxo Group Limited Novel heterocyclic compounds
CA2705318C (en) 2007-11-15 2013-12-31 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
JP5285709B2 (en) 2007-11-16 2013-09-11 ギリアード サイエンシス インコーポレーテッド Human immunodeficiency virus replication inhibitor
US20100256199A1 (en) * 2007-11-30 2010-10-07 Glaxo Group Limited Crystalline form of an Antimalarial Compound
EP2246329A1 (en) 2009-01-19 2010-11-03 Glaxo Group Limited 4(1H)-pyridinone derivatives and their use as antimalaria agents
WO2010081904A1 (en) 2009-01-19 2010-07-22 Glaxo Group Limited 4 ( 1h) -pyridinone derivatives and their use as antimalaria agents
TW201039834A (en) 2009-02-20 2010-11-16 Glaxo Group Ltd Novel heterocyclic compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5287171A (en) * 1976-01-17 1977-07-20 Nisshin Flour Milling Co Ltd Gamma-pyrone, gamma-pyridone compounds, preparation and medicines consisting of them
GB2029403A (en) * 1977-06-27 1980-03-19 Lilly Co Eli Hercicidal pyridones and pyridinethiones
US4235619A (en) * 1977-06-27 1980-11-25 Eli Lilly And Company Method of controlling aquatic weeds and algae

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL124395C (en) * 1963-09-25
FR1451373A (en) * 1965-07-06 1966-01-07 New pyridine derivatives which can be used in particular as parasiticides, and process for their preparation
JPS448514Y1 (en) * 1966-09-10 1969-04-04
GB1291571A (en) * 1969-03-29 1972-10-04 Fisons Pharmaceuticals Ltd Aza chromone-2-carboxylic acids
DE2162238C3 (en) * 1971-12-15 1981-07-02 C.H. Boehringer Sohn, 6507 Ingelheim 2-Methyl-3,5-diiodo-4-hydroxy-6-chloropyridine derivatives, process for their preparation and herbicidal compositions containing them
JPS6059236B2 (en) * 1977-07-06 1985-12-24 日清製粉株式会社 γ-pyrone derivatives, their production methods, and agricultural drugs comprising these compounds
GB8310140D0 (en) * 1983-04-14 1983-05-18 Wellcome Found Antiprotozoal agents
EP0304057B1 (en) * 1987-08-18 1994-04-20 Kumiai Chemical Industry Co., Ltd. Pyridinone derivatives, and agricultural and horticultural fungicidal compositions containing the same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5287171A (en) * 1976-01-17 1977-07-20 Nisshin Flour Milling Co Ltd Gamma-pyrone, gamma-pyridone compounds, preparation and medicines consisting of them
GB2029403A (en) * 1977-06-27 1980-03-19 Lilly Co Eli Hercicidal pyridones and pyridinethiones
US4235619A (en) * 1977-06-27 1980-11-25 Eli Lilly And Company Method of controlling aquatic weeds and algae

Also Published As

Publication number Publication date
OA09684A (en) 1993-05-15
HU9202903D0 (en) 1993-04-28
AP9100243A0 (en) 1991-04-30
FI924071A0 (en) 1992-09-11
NZ237377A (en) 1993-10-26
ZA911791B (en) 1992-11-25
CS63591A2 (en) 1991-12-17
CA2078147A1 (en) 1991-09-13
MY106873A (en) 1995-08-30
IL97501A0 (en) 1992-06-21
GB9005518D0 (en) 1990-05-09
FI924071A (en) 1992-09-11
PT97002A (en) 1991-11-29
TW201734B (en) 1993-03-11
WO1991013873A1 (en) 1991-09-19
HUT68035A (en) 1995-05-29
JPH05504961A (en) 1993-07-29
EP0447164A1 (en) 1991-09-18
IE910790A1 (en) 1991-09-25
IL97501A (en) 1995-03-15

Similar Documents

Publication Publication Date Title
AP271A (en) New pyridones and the use of pyridones in chemotherapy.
US20070244155A1 (en) Bicyclic carboxylic acid derivatives useful for treating metabolic disorders
JPH11500748A (en) 3,4-Diaryl-2-hydroxy-2,5-dihydrofuran as prodrug of COX-2 inhibitor
JP2001516742A (en) 2,3,5-Trisubstituted pyridines as cyclooxygenase-2 inhibitors
EP0072529B1 (en) Sulfur-substituted phenoxypyridines having antiviral activity
EP2351739B1 (en) 2-(4-substituted phenylamino) polysubstituted pyridine compounds as the inhibitors of non-nucleoside hiv reverse transcriptase, praparation methods and uses thereof
US5403934A (en) Heterocyclic compounds
US20130023567A1 (en) Novel Compounds
AU644425B2 (en) Heterocyclic compounds
US9296696B2 (en) Aryl derivatives and uses thereof
JP4762917B2 (en) Non-nucleoside reverse transcriptase inhibitors
WO2016104451A1 (en) Novel heterocyclic derivative
EP0178633B1 (en) 2-phenylpyrano[2,3-b]pyridines
JP2002506851A (en) Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment
AP57A (en) Pyrimidine derivatives.
US6653311B1 (en) 5-lipoxygenase inhibitors: (2-azinylamino) quinone derivatives
TW201307254A (en) Diphenyl-amine derivatives: uses, process of synthesis and pharmaceutical compositions